Neutropenic Fever
Neutropenic fever is a medical emergency defined as a single oral temperature ≥38.3°C (or ≥38.0°C sustained over one hour) in a patient with an absolute neutrophil count <500 cells/µL or expected to decline to that level, most commonly occurring after cytotoxic chemotherapy and requiring urgent empiric broad-spectrum antibiotic therapy.
Neutropenic Fever
Neutropenic fever ("neutropenic" from Latin neuter = neither + Greek penia = poverty, i.e. poverty of neutrophils; "fever" from Latin febris = heat) is a medical emergency defined by the co-occurrence of fever in a patient who is neutropenic, most commonly as a complication of cytotoxic chemotherapy or haematological malignancy.
Formal Definitions
Neutropenic fever is defined as: [1][2][3]
- Neutropenia: ANC ≤ 0.5 × 10⁹/L (500/µL), OR ANC ≤ 1.0 × 10⁹/L with a predicted decline to ≤ 0.5 × 10⁹/L within 24–48 hours
- Fever: Single oral temperature ≥ 38.3°C, OR persistent temperature ≥ 38.0°C sustained over ≥ 1 hour
Grading of neutropenia [3][4]:
| Grade | ANC Threshold | Clinical Significance |
|---|---|---|
| Neutropenia | ≤ 1.5 × 10⁹/L (≤ 1500/µL) | Mild — low infection risk |
| Severe neutropenia | ≤ 0.5 × 10⁹/L (≤ 500/µL) | Clinically significant; risk of infection rises sharply |
| Profound neutropenia | ≤ 0.1 × 10⁹/L (≤ 100/µL) | Very high risk; highest mortality |
How to Calculate ANC
ANC = Total WBC × (% Neutrophils + % Bands) / 100
For example, WBC 2.0 × 10⁹/L with 20% neutrophils and 5% bands → ANC = 2.0 × 0.25 = 0.5 × 10⁹/L = severe neutropenia.
Remarks on Temperature
Normal fever is defined by oral temperature > 37.6°C (Lecture notes) [3]. However, for neutropenic fever the IDSA thresholds (≥ 38.3°C single or ≥ 38.0°C sustained ≥ 1 h) are used because minor temperature fluctuations are common; the higher threshold avoids over-treating. That said, in immunocompromised patients, any temperature elevation should prompt clinical suspicion — these patients may be unable to mount a normal febrile response.
- Neutropenic fever occurs in 10–50% of patients with solid tumours, but the risk is much higher in haematological malignancies [1][5][6]
- It is one of the commonest haemato-oncological emergencies [2]
- Mortality is approximately 11% overall, rising to ~50% if septic shock develops [5]
- In Hong Kong, haematological malignancies (AML, ALL, lymphoma receiving intensive chemotherapy) and patients undergoing haematopoietic stem cell transplantation (HSCT) represent the highest-risk populations
- Incidence per chemotherapy cycle varies by regimen intensity:
- Dose-dense or myeloablative regimens (e.g. induction for AML): virtually 100%
- Standard regimens for solid tumours (e.g. breast, lung): 10–20% per cycle without G-CSF prophylaxis
3. Risk Factors
Understanding the risk factors is critical for risk stratification, which guides whether a patient needs inpatient IV antibiotics vs. can be managed as outpatient.
- Rate of fall of ANC — a precipitous drop is higher risk than a slow decline [5]
- Absolute level of ANC — ANC < 0.5 × 10⁹/L is the threshold; ANC < 0.1 × 10⁹/L (profound) confers highest risk [5]
- Duration of neutropenia ≥ 7 days — prolonged neutropenia dramatically increases the risk of invasive fungal infections [1][5]
Why does prolonged neutropenia matter so much? Because neutrophils are the first-line innate immune defence against bacteria and fungi. Once the marrow reserve is exhausted and the ANC remains low, the mucosal barriers (damaged by chemotherapy) become the only — and insufficient — defence. After ~7 days, fungi (which grow more slowly than bacteria) have enough time to invade tissue.
- Number and dose of chemotherapy agents used [5]
- Type of cancer: haematological malignancies, bone marrow transplant, advanced stage [5]
- Obstructions (lymphatics, GI tract, urinary tract, biliary tract) — stasis promotes bacterial colonisation [5]
- Presence of foreign bodies (indwelling venous catheters/Hickman lines, ureteric stents, biliary stents) — provide a surface for biofilm formation [5]
- Advanced age [5]
- Poor performance status [5]
- Organ dysfunction (renal, hepatic) [5]
- Pre-existing co-morbidities (diabetes mellitus, COPD, etc.)
- Mucositis severity — chemotherapy damages rapidly dividing mucosal epithelium, breaking the gut barrier and allowing translocation of gut flora
High Yield – Risk Factors for Neutropenic Fever
"The degree and duration of neutropenia" is the single most important determinant of infection risk in the immunocompromised host [7].
4. Anatomy and Function: Why Neutrophils Are the Key Players
Neutrophils (from Latin neuter = neither, referring to their neutral staining with both acidic and basic dyes; Greek philos = loving) are the most abundant circulating white blood cells (40–70% of total WBC). They are the first responders of the innate immune system.
Neutrophil lifecycle:
- Production: Bone marrow (myeloid stem cell → myeloblast → promyelocyte → myelocyte → metamyelocyte → band → mature segmented neutrophil). This takes ~10–14 days.
- Bone marrow reserve: A large pool of mature neutrophils is stored in the marrow, ready for rapid release (this is why early in infection, the WCC can rise rapidly — it's releasing reserves).
- Circulation: Mature neutrophils circulate for only ~2–3 days before undergoing apoptosis [1]. This very short lifespan explains why neutropenia develops so rapidly after chemotherapy.
- Tissue migration: Neutrophils are recruited to infection sites by chemokines; they phagocytose and kill bacteria via oxidative burst (reactive oxygen species) and degranulation (proteases, defensins).
Neutrophil nadir usually occurs on Day 7–10 after chemotherapy when all marrow reserve is depleted [1][2]. This varies between agents — Taxanes (e.g. paclitaxel, docetaxel) cause earlier nadir at Day 4–5; post-bone marrow transplant nadir occurs around Day 21 [5].
The GI tract, oropharynx, and skin are the three main sources of infection in neutropenic patients. Under normal conditions:
- The intestinal mucosa has a single layer of columnar epithelium with tight junctions, a mucus layer, secretory IgA, and commensal bacteria that competitively exclude pathogens
- Chemotherapy (especially agents like cytarabine, methotrexate, 5-FU) destroys rapidly dividing mucosal cells → mucositis → breakdown of this barrier → bacterial translocation from the gut lumen into the bloodstream
- Similarly, skin integrity is breached by indwelling catheters, bone marrow biopsy sites, and chemotherapy-induced dermatitis
The body's defence against infection can be conceptualized in layers [8]:
| Layer | Component | Examples |
|---|---|---|
| Physical barriers | Skin, mucous membranes, cilia, gastric acid | Disrupted by chemotherapy-induced mucositis, catheters |
| Innate immunity | Neutrophils, macrophages, NK cells, complement | Neutropenia removes the most critical component |
| Adaptive immunity | T cells, B cells, immunoglobulins | Impaired by lymphocyte-depleting agents (fludarabine, alemtuzumab), steroids, anti-CD20 |
In neutropenic fever, the problem is primarily at the innate immunity level — neutrophils cannot be recruited to sites of infection, so bacteria multiply unchecked.
5. Aetiology
Key Principle
Pathogens can only be identified (culture-positive) in 20–30% of neutropenic fever episodes [1][5]. The majority are fever of unknown origin (FUO) or clinically documented infections (clinical site identified but no organism isolated). This is why empirical broad-spectrum antibiotics must be given immediately — you treat before you identify.
5.1 Bacterial Pathogens (Most Common Cause)
Gram-positive bacteria have become the most common identified organisms due to the increased use of indwelling intravascular catheters [1][7]:
| Organism | Source / Association | Pathophysiology |
|---|---|---|
| Coagulase-negative Staphylococci (e.g. S. epidermidis) | Most common organism identified overall [3]; associated with indwelling catheters | Forms biofilm on catheter surfaces; low virulence but persistent bacteraemia |
| S. aureus | Skin lesions, indwelling catheter, central line [1] | More virulent; can cause metastatic infections (e.g. endocarditis, osteomyelitis) |
| Viridans streptococci | Dental abscess, substantial mucosal damage from chemotherapy [1] | Oral commensals translocate through damaged mucosa; can cause viridans streptococcal shock syndrome |
| Enterococci (E. faecalis, E. faecium) | GI tract translocation, urinary tract | Intrinsically resistant to cephalosporins; VRE is a growing concern |
Gram-negative bacilli were traditionally the commonest cause and remain associated with the most severe infections due to endotoxaemia [1][7]:
| Organism | Source | Why It Matters |
|---|---|---|
| Pseudomonas aeruginosa | Environmental, hospital-acquired [1][2][7] | Associated with the most serious infections; produces exotoxins, forms biofilms; high mortality if not covered empirically |
| E. coli | GI tract translocation [2][7] | Most common Gram-negative isolate in many centres |
| Klebsiella spp. | GI tract, biliary | ESBL-producing strains increasing in HK |
| Other Enterobacterales | GI translocation | Includes Enterobacter, Serratia, Proteus |
Why is Pseudomonas so dangerous? Pseudomonas produces endotoxin (LPS → TLR4 activation → cytokine storm → septic shock) and multiple virulence factors (exotoxin A, elastases, pyocyanin). In a neutropenic patient who cannot mount an immune response, Pseudomonas bacteraemia can progress to fulminant sepsis within hours. This is why anti-pseudomonal cover is mandatory in empirical regimens.
Fungal infections usually occur in haematological malignancies and prolonged neutropenia (> 7 days) [1][7]:
| Organism | Type | Clinical Features |
|---|---|---|
| Candida spp. | Yeast | Oral thrush, oesophageal candidiasis, candidaemia; think of this with mucosal damage |
| Aspergillus spp. | Mould (filamentous fungus) | Invasive pulmonary aspergillosis — presents with persistent fever despite broad-spectrum antibiotics, pleuritic chest pain, haemoptysis; CT shows "halo sign" (ground-glass surrounding nodule) or "air-crescent sign" |
| Pneumocystis jirovecii (PCP) | Atypical fungus | More common with T-cell deficiency (steroids, HIV); diffuse bilateral ground-glass on CXR/CT |
| Mucorales (Mucormycosis) | Mould | Rhinocerebral or pulmonary; rapidly fatal; associated with uncontrolled DM, prolonged neutropenia |
Why do fungi appear later? Fungi replicate more slowly than bacteria. The initial bacterial flora are kept in check by empirical antibiotics, but fungi are not covered by standard antibacterial agents. After ~7 days of neutropenia and broad-spectrum antibiotics, the normal competitive flora are eliminated, and fungi (which are already colonising mucosal surfaces) can invade.
Human herpesviruses are common in high-risk patients with chemotherapy-induced mucositis [3][4]:
- Reactivation of HSV-1 and HSV-2 (herpes simplex) — painful oral/genital ulcers
- Reactivation of VZV (varicella-zoster virus) — dermatomal vesicular rash (shingles) or disseminated in severe immunosuppression
- Reactivation of CMV/EBV/HHV-6 — can occur as a result of immunosuppression or receipt of blood products/stem cells [3][4]
- Respiratory viruses: Influenza, parainfluenza, adenovirus, RSV — documented with increasing frequency [3][4]; important in HK during winter influenza season
- Tuberculosis (TB): In HK (an endemic area for TB), extrapulmonary TB should be considered [5]; may present atypically
- Parasitic: Strongyloides hyperinfection in patients from endemic areas receiving steroids
Most infections come from the GI tract, aerodigestive tract, and skin (from catheter) [1]:
6. Pathophysiology
Understanding the pathophysiology of neutropenic fever requires integrating the concepts of chemotherapy-induced marrow suppression, mucosal barrier breakdown, and impaired immune surveillance.
Step-by-step explanation:
-
Chemotherapy targets rapidly dividing cells — this includes both malignant cells and normal haematopoietic progenitors in the bone marrow. Neutrophil precursors (myeloblasts, promyelocytes) are destroyed.
-
Neutrophil lifespan is only ~2–3 days [1], so the circulating neutrophils die off quickly. Initially, the bone marrow reserve compensates. By Day 7–10, both circulating and reserve neutrophils are depleted → nadir.
-
Simultaneously, chemotherapy damages the mucosal epithelium of the GI tract (which also turns over rapidly, every 3–5 days). This causes mucositis — the mucosal barrier becomes ulcerated and permeable.
-
Commensal bacteria (E. coli, Klebsiella from the gut; viridans streptococci from the mouth; S. epidermidis from the skin around catheters) now have a portal of entry into the bloodstream.
-
Without neutrophils to phagocytose and kill these organisms, they proliferate unchecked in the blood → bacteraemia.
-
Fever is triggered by: (a) bacterial products (e.g. LPS from Gram-negative bacteria) acting as exogenous pyrogens; (b) endogenous pyrogens (IL-1, IL-6, TNF-α) released from residual macrophages and monocytes → these act on the hypothalamic thermoregulatory centre via prostaglandin E2 → raise the temperature set point.
-
If the bacteria are Gram-negative (especially Pseudomonas), their endotoxin (LPS) can trigger a massive inflammatory cascade → vasodilation, capillary leak, DIC → septic shock → death within hours if untreated.
Clinical features may be subtle due to diminished inflammatory response associated with myelosuppression [1]
This is a critically important concept. The classical signs of infection (redness, swelling, warmth, pus formation) all require neutrophil recruitment:
- Redness and warmth = vasodilation from inflammatory mediators → partly present (macrophages can still release cytokines) but attenuated
- Swelling = fluid exudation → partly present
- Pus = collection of dead neutrophils → absent because there are no neutrophils to form pus [4]
- Consolidation on CXR in pneumonia may be absent because radiographic infiltrates require inflammatory cell infiltration of the alveoli [5]
Therefore, fever is often the only presenting sign [1]. You cannot rely on the usual clinical features to diagnose infection. You must treat empirically.
7. Classification
Risk stratification determines the intensity of management:
| Feature | High Risk | Low Risk |
|---|---|---|
| Duration of neutropenia | Anticipated ≥ 7 days | Expected ≤ 7 days |
| Depth of neutropenia | ANC < 0.1 × 10⁹/L (profound) | ANC 0.1–0.5 |
| Comorbidities | Haemodynamically unstable, deranged LRFT, altered mental state | None significant |
| Cancer type | Haematological malignancy, HSCT | Solid tumour |
| MASCC score | < 21 | ≥ 21 |
| Management | Inpatient IV antibiotics | Outpatient oral antibiotics (seldom done in HK) [5] |
MASCC (Multinational Association for Supportive Care in Cancer) Risk Index Score:
| Characteristic | Weight |
|---|---|
| Burden of illness: no or mild symptoms | 5 |
| Burden of illness: moderate symptoms | 3 |
| No hypotension (SBP ≥ 90) | 5 |
| No COPD | 4 |
| Solid tumour or no previous fungal infection | 4 |
| No dehydration requiring IV fluids | 3 |
| Outpatient at onset of fever | 3 |
| Age < 60 years | 2 |
| Maximum score | 26 |
MASCC score ≥ 21 → Low risk (positive predictive value ~91%) MASCC score < 21 → High risk
HK Practice
In Hong Kong, low-risk outpatient management is seldom practised [5]. Most neutropenic fever patients are admitted for inpatient IV antibiotics, partly because of the high density of hospital care and ease of access. However, the MASCC score is still tested in exams.
Neutropenic fever episodes are classified based on whether an organism or site is identified:
| Category | Definition | Frequency |
|---|---|---|
| Microbiologically documented infection (MDI) | Pathogen identified by culture + clinical infection | ~20–30% |
| Clinically documented infection (CDI) | Clinical site of infection identified (e.g. pneumonia on CXR) but no organism isolated | ~20–30% |
| Fever of unknown origin (FUO) | No site or organism identified despite workup | ~50% |
8. Clinical Features
Cardinal Rule
Signs of inflammation can be extremely subtle in the absence of neutrophils. Pus is NOT found due to lack of neutrophils [4]. Do not expect the classical features of infection. A neutropenic patient who "looks well" may be hours away from septic shock. Treat the fever, not the appearance.
| Symptom | Pathophysiological Basis | Notes |
|---|---|---|
| Fever | Exogenous pyrogens (bacterial products like LPS) and endogenous pyrogens (IL-1, IL-6, TNF-α from residual macrophages) → hypothalamic PGE₂ → raised temperature set point | Often the ONLY presenting symptom [1]. May be blunted by steroids, NSAIDs, or antipyretics |
| Rigors / chills | Muscle contraction to generate heat when hypothalamic set point is raised; especially associated with bacteraemia (particularly Gram-negative) | Presence of rigors increases suspicion of blood-stream infection |
| Sore throat / dysphagia | Oral mucositis from chemotherapy → breakdown of oral mucosal barrier → secondary infection by oral flora (Candida, HSV, viridans streptococci) | Ask specifically; look for white plaques (Candida) or vesicles (HSV) |
| Cough / dyspnoea | Pneumonia — but CXR infiltrates may be absent [5] due to inability to mount inflammatory exudate; or may be present with atypical organisms | Consider bacterial, fungal (Aspergillus), viral (RSV, influenza), PCP |
| Abdominal pain / diarrhoea | Neutropenic enterocolitis (typhlitis) — inflammation and necrosis of the caecum/ascending colon; or C. difficile colitis from antibiotic exposure | Abdominal pain + diarrhoea in a neutropenic patient = typhlitis until proven otherwise |
| Perianal pain | Perianal abscess/cellulitis — but without pus formation; the perianal area is rich in bacteria from the GI tract and is a common entry site | Avoid digital rectal examination (DRE) as it can traumatise fragile mucosa and introduce infection [4] |
| Skin lesions / rash | May indicate disseminated infection (e.g. ecthyma gangrenosum from Pseudomonas — necrotic skin lesion), HSV vesicles, VZV dermatomal rash | Any new skin lesion in a neutropenic patient should be biopsied and cultured |
| Catheter site pain / redness | Line sepsis — biofilm on catheter surface → bacteraemia | Always inspect catheter exit sites |
| Decreased oral intake / mental obtundation | Suggests sepsis [4] — hypoperfusion of CNS, metabolic derangement | A subtle sign that should prompt escalation |
| Urinary symptoms (dysuria, frequency) | UTI — less common source but still possible, especially with urinary catheters | May be masked; pyuria may be absent (no neutrophils to produce WBCs in urine) |
Full history and physical examination (done daily) should focus on: [9]
| Site to Examine | What to Look For | Pathophysiological Basis |
|---|---|---|
| Skin | Erythema, cellulitis, ecthyma gangrenosum (black necrotic lesions — pathognomonic for Pseudomonas), herpetic vesicles, catheter exit site erythema | Skin is a major portal of entry; necrotic lesions occur because neutrophils cannot wall off infection |
| Oral cavity | Mucositis (erythema, ulceration), white plaques (Candida), vesicles (HSV), dental abscess | Chemotherapy damages oral epithelium; oral flora (viridans streptococci, Candida) invade |
| Lungs | Crackles, reduced breath sounds, dullness to percussion | Pneumonia — but auscultatory findings may be minimal without neutrophilic inflammation |
| Abdomen | Abdominal tenderness, peritoneal signs → may represent neutropenic enterocolitis or C. difficile colitis [4] | Caecal inflammation ± necrosis; can perforate |
| Perianal area | Erythema, pain, tender haemorrhoids suggesting infection [4] | DO NOT perform DRE |
| IV catheter sites / Hickman exit site | Erythema and tenderness suggesting infection; MUST exclude line sepsis [4][9] | Biofilm-associated infection |
| BM biopsy site | Erythema, tenderness, discharge | Recent procedural wound — portal of entry |
| Nasal sinuses | Tenderness over sinuses, nasal discharge, facial pain | Fungal sinusitis (Aspergillus, Mucor) in prolonged neutropenia [9] |
| Vital signs | BP, Pulse, Temperature, RR, SpO₂, GCS [4] | Haemodynamic instability suggests sepsis/septic shock |
| General appearance | Ill-looking, mental obtundation, decreased oral intake [4] | Suggests systemic sepsis |
"Full Hx & P/E (daily): skin, oral, lung, abdomen, perianal, Hickman exit, BM Bx site; over nasal sinus" [9]
8.3 Special Clinical Scenarios
- "Typhlitis" from Greek typhlon = caecum
- Necrotising inflammation of the caecum (and sometimes other parts of the colon) occurring in neutropenic patients
- Pathogenesis: chemotherapy → mucosal damage to caecal wall + neutropenia → invasion by gut bacteria → transmural inflammation ± necrosis ± perforation
- Why the caecum? The caecum has the thinnest wall and poorest blood supply of the large bowel, making it most vulnerable
- Clinical features: RIF pain, diarrhoea (may be bloody), fever, abdominal distension
- Diagnosis: CT abdomen showing caecal wall thickening, pericolonic fat stranding ± pneumatosis
- Complications: perforation, peritonitis, septic shock — surgical emergency
- Pathognomonic skin lesion of Pseudomonas aeruginosa bacteraemia
- Begins as painless red macule → rapidly progresses to haemorrhagic bulla → central black necrotic eschar with erythematous halo
- Pathogenesis: Pseudomonas invades blood vessel walls (vasculitis) → thrombosis → ischaemic necrosis of overlying skin
- May occur at any site but commonly in perineum, axilla, or extremities
Before we discuss investigations and management (which will be covered in the next response), it is important to understand the clinical approach:
The key principle: neutropenic fever is a medical emergency because unchecked proliferation of bacteria can lead to rapid progression into septic shock, especially in Gram-negative sepsis [1]. Empirical antibiotics must be started ASAP after immediate septic workup — ideally < 1–2 hours after presentation [1].
Neutropenic Card
Patients receiving chemotherapy are given a "neutropenic card" — they are taught to present this card to any healthcare provider if they develop fever, so that empirical antibiotics can be started immediately without delay [2].
| Principle | Explanation |
|---|---|
| Why is fever often the only sign? | Neutrophils are required for pus formation, tissue erythema/swelling, and CXR consolidation. Without neutrophils, these classical signs are absent. |
| Why cover Pseudomonas empirically? | Pseudomonas causes the most fulminant sepsis via endotoxin; mortality without adequate cover is extremely high. |
| Why do fungal infections occur after 7 days? | Fungi grow slowly; they emerge when prolonged neutropenia + broad-spectrum antibiotics eliminate competing bacteria. |
| Why is the GI tract the main source? | Chemotherapy causes mucositis → breaks the mucosal barrier → allows translocation of gut bacteria into the bloodstream. |
| Why has Gram-positive become more common? | Increased use of indwelling catheters (Hickman lines, PICCs) provides a surface for biofilm formation by skin commensals (CoNS, S. aureus). |
| Why does nadir occur at Day 7–10? | Neutrophil lifespan is ~2–3 days. After chemotherapy kills the progenitors, the marrow reserve sustains levels for a few more days before being exhausted. |
High Yield Summary
Definition:
- Neutropenic fever = ANC ≤ 0.5 × 10⁹/L (or ≤ 1.0 with predicted decline to ≤ 0.5 in 48h) + single oral temp ≥ 38.3°C or sustained ≥ 38.0°C for ≥ 1 hour
Key Numbers:
- Occurs in 10–50% of solid tumours; higher in haematological malignancies
- Only 20–30% are culture-positive
- Mortality ~11% overall, ~50% with septic shock
- Nadir: Day 7–10 (Taxanes D4–5; post-HSCT D21)
- Neutrophil lifespan: ~2–3 days
Risk Factors: Duration and depth of neutropenia are most important; prolonged ( ≥ 7 days) and profound ( < 0.1) = highest risk
Pathogens:
- Gram-positive now most common (CoNS, S. aureus, viridans strep) — due to catheters
- Gram-negative most dangerous (Pseudomonas, E. coli) — endotoxin → septic shock
- Fungal (Candida, Aspergillus) — with prolonged neutropenia > 7 days
- Viral reactivation (HSV, VZV, CMV)
Clinical Features:
- Fever is often the ONLY sign
- Pus is NOT formed (no neutrophils)
- CXR may be normal despite pneumonia
- Examine: skin, oral cavity, lungs, abdomen, perianal area, catheter sites, BM biopsy sites, sinuses — DAILY
- Avoid DRE
Principle: Medical emergency — start empirical broad-spectrum anti-pseudomonal antibiotics within 1 hour of presentation
Active Recall - Neutropenic Fever (Definition, Epidemiology, Aetiology, Pathophysiology, Clinical Features)
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 423, Complications of Leukemia — Neutropenic Fever) [2] Senior notes: Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf (p. 11, Haematological Emergencies — Neutropenic fever) [3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 1329–1331, Neutropenic fever) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 572–574, Neutropenic fever) [5] Senior notes: Maksim Medicine Notes.pdf (p. 49, Clinical oncology — Neutropenic fever) [6] Senior notes: Ryan Ho Haemtology.pdf (p. 70, Complications of Leukaemia — Neutropenic Fever) [7] AOS material: AOS - Microbio.pdf (p. 5, Neutropenic fever pathogens) [8] Lecture slides: GC 100. Defense against microbes.pdf [9] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts.pdf (p. 8, Approach to Mx of neutropenic fever)
Differential Diagnosis of Neutropenic Fever
When a patient on chemotherapy (or with known haematological malignancy) presents with fever and neutropenia, the immediate clinical reflex is to treat for infection empirically. However, a systematic differential diagnosis is still essential for two reasons:
- Not all fevers in neutropenic patients are infectious — non-infectious causes must be considered, especially if fever persists despite broad-spectrum antibiotics.
- Among infectious causes, identifying the site and organism changes the antibiotic/antifungal strategy and duration.
The differential diagnosis of neutropenic fever is really two questions running in parallel:
- Question 1: Is this fever due to infection, or is there a non-infectious cause?
- Question 2: If infectious, where is the source and what is the organism?
Pathogens can only be identified in 20–30% of neutropenic fever episodes [1][6]. The remainder are either clinically documented infections (a site is found but no organism isolated) or fever of unknown origin (~50%) [5]. This makes the differential diagnosis a process of active exclusion rather than definitive identification.
I. Infectious Causes (The Primary Concern)
This is the most important category. In a neutropenic patient, you must assume infection until proven otherwise and treat empirically, because delay kills.
A. Bacterial Infections
Gram-positive bacteria have become the most common identified organisms with increased use of indwelling intravascular catheters [1][2][7].
| Organism | Typical Source / Clue | Why It Matters |
|---|---|---|
| Coagulase-negative Staphylococci (CoNS, e.g. S. epidermidis) | Most common organism identified overall [3][4]; indwelling CVC / Hickman line | Low virulence but persistent; forms biofilm on catheter → line sepsis; may be dismissed as contaminant (need ≥ 2 positive cultures from different sites to confirm) |
| S. aureus | Skin lesions, indwelling catheter, central line [1] | Higher virulence; metastatic complications (endocarditis, osteomyelitis, septic arthritis); always significant when isolated |
| Viridans group streptococci | Dental abscess, chemotherapy-induced oral mucositis [1] | Can cause viridans streptococcal shock syndrome (especially with high-dose cytarabine); ~10% mortality |
| Enterococci (E. faecalis, E. faecium) | GI translocation, urinary tract, intra-abdominal | Intrinsically resistant to cephalosporins; VRE (vancomycin-resistant enterococci) emerging in HK |
| Streptococcus pneumoniae | Respiratory tract | More common in patients with very low immunoglobulin levels (hypogammaglobulinaemia) [7] |
Line Sepsis — Always Consider
MUST exclude line sepsis in any neutropenic patient with a central venous catheter [3][4][9]. A patient with fever + erythema/tenderness at the Hickman exit site has line sepsis until proven otherwise. Blood cultures should be drawn from both the CVC (through two different ports) and from a peripheral venous puncture [9] — differential time to positivity (DTTP) ≥ 2 hours earlier from the CVC line suggests catheter-related bloodstream infection.
Gram-negative bacilli were traditionally the commonest organisms and remain associated with the most severe infections due to endotoxaemia [1][2][7].
| Organism | Typical Source / Clue | Why It Matters |
|---|---|---|
| E. coli | GI tract translocation [2][7] | Most common Gram-negative isolate in many centres; can produce ESBL (extended-spectrum beta-lactamases) — increasingly common in HK |
| Pseudomonas aeruginosa | Hospital-acquired, environmental [1][2][7] | Associated with the most serious infection [1]; ecthyma gangrenosum (pathognomonic necrotic skin lesion); high mortality if inadequate cover |
| Klebsiella spp. | GI tract, biliary | ESBL-producing and carbapenem-resistant strains increasing globally and in HK |
| Enterobacter, Serratia, Proteus | GI translocation, nosocomial | May demonstrate inducible AmpC resistance → can appear susceptible initially but develop resistance on cephalosporins |
Why is Gram-negative sepsis so feared? The lipopolysaccharide (LPS / endotoxin) in the Gram-negative outer membrane is a potent activator of TLR4 on macrophages → massive release of TNF-α, IL-1β, IL-6 → systemic inflammatory response → vasodilatory shock, DIC, multi-organ failure. Without neutrophils to contain the infection early, this cascade can become irreversible within hours.
| Organism | Typical Source / Clue | Why It Matters |
|---|---|---|
| Clostridium difficile | Antibiotic-associated diarrhoea — prior broad-spectrum antibiotics disrupt colonic flora | Diagnose by stool C. difficile cytotoxin assay or PCR [3][4][9]; treatment: oral vancomycin or fidaxomicin |
| Bacteroides fragilis | Intra-abdominal / perianal sepsis | Should be considered in patients with abdominal/perianal symptoms |
| Fusobacterium | Oropharyngeal source, dental infection | Lemierre syndrome (internal jugular vein thrombophlebitis) — rare but notable |
- Mycobacterium tuberculosis: In Hong Kong (endemic area), extrapulmonary TB should always be considered [5], especially with prolonged fever unresponsive to antibiotics. May present atypically — miliary pattern, hepatic/splenic involvement, bone marrow infiltration
- Atypical mycobacteria (NTM, e.g. M. avium complex): In severely immunosuppressed (especially post-HSCT, HIV co-infection)
- Nocardia: Filamentous Gram-positive rod; presents with pulmonary nodules, brain abscess, skin lesions; consider in patients on prolonged steroids
Fungal infections usually occur in haematological malignancies and prolonged neutropenia (> 7 days) [1][7]. They are the second most important category after bacteria and typically emerge when initial antibacterial therapy has failed.
| Organism | Type | Clinical Clue / Source | Key Diagnostic Feature |
|---|---|---|---|
| Candida spp. | Yeast [7] | Oral thrush (white plaques), oesophageal candidiasis (odynophagia), candidaemia (persistent fever despite antibiotics + CVC in situ) | Blood culture (but sensitivity only ~50%); serum β-D-glucan |
| Aspergillus spp. | Mould [7] | Persistent fever despite broad-spectrum antibiotics > 4–7 days; pleuritic chest pain, haemoptysis; pulmonary nodules | CT thorax: "halo sign" (ground-glass halo around nodule), later "air-crescent sign"; serum galactomannan [9]; BAL culture/galactomannan |
| Pneumocystis jirovecii (PCP/PJP) | Atypical fungus [5][10] | Progressive dyspnoea, dry cough, hypoxia; bilateral ground-glass opacities on CXR/CT; ↑LDH, ↑β-D-glucan [10] | Induced sputum or BAL for silver stain/IF/PCR; cannot be cultured [10] |
| Mucorales (Rhizopus, Mucor) | Mould | Rhinocerebral (facial pain, necrotic eschar on palate/nasal mucosa) or pulmonary; associated with uncontrolled DM, prolonged neutropenia | Tissue biopsy showing broad, non-septate, ribbon-like hyphae with 90° branching |
| Talaromyces (Penicillium) marneffei | Dimorphic fungus | Important in Southern China / HK and Southeast Asia; associated with advanced HIV; disseminated disease with skin papules with central umbilication, hepatosplenomegaly | Blood/tissue culture; histology showing intracellular yeast with central septum |
Serial serum galactomannan and 1,3 β-D-glucan testing is part of the monitoring strategy in high-risk neutropenic patients [9].
When to Suspect Fungal Infection
Think of invasive fungal infection when:
- Fever persists > 4–7 days despite adequate broad-spectrum antibiotics
- Neutropenia is prolonged (≥ 7 days) or profound (ANC < 0.1)
- Patient has a haematological malignancy or is post-HSCT
- New pulmonary nodules or sinus symptoms develop
Human herpesviruses are common in high-risk patients with chemotherapy-induced mucositis [3][4]:
| Virus | Mechanism | Clinical Clue |
|---|---|---|
| HSV-1 / HSV-2 | Reactivation in setting of immunosuppression + mucosal damage | Painful oral/labial vesicles/ulcers; genital lesions; may disseminate |
| VZV | Reactivation (prior varicella) | Dermatomal vesicular rash (shingles); can disseminate with multi-dermatomal or visceral involvement |
| CMV | Reactivation especially post-HSCT, post solid-organ transplant | Colitis (bloody diarrhoea), pneumonitis, retinitis; diagnose by CMV PCR (viral load) |
| EBV / HHV-6 | Reactivation due to immunosuppression or receipt of blood products/stem cells [3][4] | EBV: PTLD (post-transplant lymphoproliferative disorder); HHV-6: encephalitis post-HSCT |
| Respiratory viruses (Influenza, parainfluenza, RSV, adenovirus) | Documented with increasing frequency [3][4] | Coryza, cough, rhinorrhoea; can cause severe pneumonia in immunocompromised; multiplex PCR (NPA) for diagnosis |
Why viral reactivation? During chemotherapy, cytotoxic T-lymphocytes (which keep latent herpesviruses in check) are depleted. When immune surveillance drops, latent virus in sensory ganglia (VZV, HSV) or lymphocytes (EBV, CMV) reactivates and begins replicating.
| Pathogen | Clinical Context | Notes |
|---|---|---|
| Mycobacterium tuberculosis | Endemic in HK; extrapulmonary presentations common [5] | Disseminated / miliary TB; consider if prolonged FUO |
| Toxoplasma gondii | Post-HSCT, HIV | Brain abscess with ring-enhancing lesions |
| Strongyloides stercoralis | Patient from endemic area (SE Asia) receiving steroids | Hyperinfection syndrome with Gram-negative bacteraemia due to larvae carrying gut bacteria through bowel wall |
II. Non-Infectious Causes of Fever in Neutropenic Patients
These are important to consider, especially when fever persists despite appropriate empirical antimicrobials and all cultures remain negative. Non-infectious causes account for an estimated 30–40% of febrile episodes in neutropenic patients.
| Mechanism | Culprits | Clinical Clue |
|---|---|---|
| Hypersensitivity reaction, direct pyrogenicity, or altered thermoregulation | Cytarabine (Ara-C), bleomycin, amphotericin B, G-CSF, biological agents (rituximab, alemtuzumab), antibiotics (β-lactams, vancomycin), allopurinol | Temporal correlation with drug administration; "looks well" despite fever; may have eosinophilia or rash; resolves when offending drug is discontinued |
Why does G-CSF cause fever? G-CSF (granulocyte colony-stimulating factor) stimulates neutrophil production and release from the bone marrow. This process involves bone marrow expansion (→ bone pain) and release of pyrogenic cytokines (IL-6, TNF-α) from activated marrow cells → fever. This is a common clinical conundrum: the drug given to treat neutropenia itself causes fever, mimicking infection.
| Mechanism | Clinical Clue |
|---|---|
| Tumour cells produce endogenous pyrogens (IL-1, IL-6, TNF-α) directly, or tumour necrosis releases pyrogens | More common in haematological malignancies (lymphoma, leukaemia) than solid tumours; may be the initial presentation of relapsed/refractory disease; diagnosed by exclusion; classically responds to naproxen test (fever resolves with naproxen 250 mg BD for 3 days — "Naproxen test positive") |
Fever during or after transfusion requires consideration of three main differentials [11]:
| Type | Mechanism | Key Distinction |
|---|---|---|
| Febrile non-haemolytic transfusion reaction (FNHTR) | Most common cause; cytokines released from residual leucocytes in blood products act as pyrogens | Fever is NOT a contraindication for continuing transfusion if FNHTR confirmed [11]; exclude ABO incompatibility and bacterial contamination first |
| ABO incompatibility (acute haemolytic transfusion reaction) | Anti-A or anti-B antibodies attack transfused RBCs → intravascular haemolysis → massive cytokine release | Fever + rigors + flank pain + dark urine + hypotension → stop transfusion immediately |
| Bacterial contamination of blood products | Bacteria (especially in platelets stored at room temperature) release endotoxin | High fever, rigors, hypotension shortly after starting transfusion → stop immediately, culture the bag |
| Context | Mechanism | Clinical Clue |
|---|---|---|
| Post-allogeneic HSCT; or after non-irradiated blood product transfusion (transfusion-associated GVHD) | Donor T-lymphocytes attack recipient tissues | Fever + skin rash (maculopapular, may be extensive) + diarrhoea + liver dysfunction (↑bilirubin, ↑ALP); usually occurs Day 14–45 post-HSCT for acute GVHD |
| Mechanism | Clinical Clue |
|---|---|
| Cancer patients are hypercoagulable (Virchow's triad: stasis from immobility, endothelial injury from CVC, hypercoagulability from malignancy); DVT/PE releases tissue factor and pyrogens | Unilateral leg swelling (DVT); pleuritic chest pain, dyspnoea, tachycardia (PE); fever is typically low-grade |
| Mechanism | Clinical Clue |
|---|---|
| Chronic steroid use (common in haem-onc regimens, e.g. dexamethasone in lymphoma/myeloma) → HPA axis suppression → adrenal crisis when steroids are abruptly withdrawn or during physiological stress | Hypotension refractory to fluids, hypoglycaemia, hyponatraemia, hyperkalaemia, fever; responds to IV hydrocortisone |
- Mucositis itself — severe mucosal inflammation can release cytokines and cause low-grade fever even without superinfection
- Engraftment syndrome — post-HSCT, when neutrophils begin to recover, the engraftment process itself can cause fever, rash, and non-cardiogenic pulmonary oedema (typically around Day 10–14 post-transplant)
- Haemophagocytic lymphohistiocytosis (HLH) / Macrophage activation syndrome — a life-threatening hyperinflammatory condition triggered by infections (especially EBV, CMV), malignancy, or drugs; presents with high fever, cytopenias, hyperferritinaemia (often > 10,000), hypertriglyceridaemia, hepatosplenomegaly
A practical approach is to think about the differential by site, as emphasised in the clinical examination:
Full Hx & P/E (daily): skin, oral, lung, abdomen, perianal, Hickman exit, BM Bx site; over nasal sinus [9]
| Site | Infectious DDx | Non-Infectious DDx |
|---|---|---|
| Skin / Catheter sites [9] | Cellulitis (S. aureus, streptococci), line sepsis (CoNS, S. aureus), ecthyma gangrenosum (Pseudomonas), HSV/VZV vesicles, fungal skin lesions | Drug rash, GVHD rash, Sweet syndrome (acute febrile neutrophilic dermatosis — paradoxically can occur even in neutropenia) |
| Oral cavity [9] | Oral candidiasis (thrush), HSV stomatitis, viridans streptococcal mucositis, dental abscess, necrotising gingivitis | Chemotherapy-induced mucositis (sterile) |
| Lungs [9] | Bacterial pneumonia (Gram-negative, Gram-positive), Aspergillus (persistent fever + nodules), PJP (bilateral GGO), CMV pneumonitis, respiratory viruses, TB | Drug-induced pneumonitis (e.g. bleomycin, methotrexate), radiation pneumonitis, pulmonary haemorrhage (thrombocytopaenia), pulmonary embolism, engraftment syndrome |
| Abdomen [9] | Neutropenic enterocolitis (typhlitis), C. difficile colitis, hepatosplenic candidiasis, cholangitis, appendicitis (may lack classical signs) | Tumour-related pain, ileus, pancreatitis (asparaginase) |
| Perianal area [9] | Perianal abscess/cellulitis (without pus formation), perianal fissure/fistula with superinfection | Haemorrhoids |
| Nasal sinuses [9] | Fungal sinusitis (Aspergillus, Mucor) — especially with prolonged neutropenia | Allergic sinusitis |
| BM biopsy site [9] | Wound infection, cellulitis | Haematoma |
| CNS | Bacterial meningitis, viral encephalitis (HSV, HHV-6), fungal meningitis (Cryptococcus), Toxoplasma brain abscess | Leukaemic / lymphomatous CNS infiltration, drug toxicity (e.g. methotrexate leukoencephalopathy) |
| Urinary tract | UTI (E. coli, Klebsiella, Enterococcus, Candida) — note that pyuria may be absent in neutropenia | Obstructive uropathy from tumour |
The timing of fever relative to the chemotherapy cycle and duration of neutropenia helps narrow the differential:
| Timing | Most Likely Pathogens | Rationale |
|---|---|---|
| Day 0–7 post-chemo | Drug fever, mucositis (sterile), early bacterial infection from pre-existing colonisation | Neutrophil count may still be adequate; mucositis developing |
| Day 7–14 post-chemo (nadir) [1][2] | Gram-positive bacteraemia (line sepsis), Gram-negative bacteraemia (GI translocation) | ANC at its lowest; mucosal barrier maximally damaged |
| > 7 days of neutropenia | Invasive fungal infection (Candida, Aspergillus) [1][7] | Fungi are slow-growing; emerge when bacteria are suppressed by antibiotics and neutropenia is prolonged |
| > 14 days of neutropenia | Moulds (Aspergillus, Mucor), viral reactivation (CMV, HHV-6) | Very prolonged immunosuppression; typically post-HSCT patients |
| Neutrophil recovery phase | Engraftment syndrome, "unmasking" of previously subclinical infection (e.g. hepatosplenic candidiasis becomes apparent as neutrophils return and mount an inflammatory response) | Paradoxical clinical deterioration as immune reconstitution reveals occult infections |
| Feature | Favours Infection | Favours Non-Infectious |
|---|---|---|
| Rigors / chills | Present (especially bacteraemia) | Absent or mild |
| Haemodynamic instability | Present in sepsis | Usually stable (except PE, adrenal crisis) |
| Localising signs | Present if site identified (though may be subtle) | Absent |
| Response to empirical antibiotics | Fever resolves within 48–72 h | Fever persists despite adequate antibiotics |
| Temporal relation to drug administration | No specific pattern | Fever onset correlates with drug timing |
| CRP / Procalcitonin trend | Rising or very high | May be elevated but stable or falling |
| Blood cultures | Positive in ~20–30% | Negative |
| Naproxen test | Negative (fever persists) | Positive (fever resolves — suggests tumour fever) |
High Yield — Persistent Fever Despite Antibiotics
If a neutropenic patient remains febrile after 4–7 days of adequate empirical antibacterial therapy, think about:
- Invasive fungal infection (Aspergillus, Candida) — most important
- Resistant organism not covered by current regimen
- Drug fever from the antibiotic itself
- Non-infectious cause (tumour fever, GVHD, VTE)
- Abscess / collection that requires drainage (CT-guided or surgical)
- Viral infection (CMV, HHV-6 reactivation)
| Category | Specific Causes | Key Clinical Clue |
|---|---|---|
| Gram-positive bacteria | CoNS, S. aureus, viridans strep, enterococci | CVC in situ, oral mucositis, skin breakdown |
| Gram-negative bacteria | E. coli, Pseudomonas, Klebsiella | GI translocation, ecthyma gangrenosum, endotoxic shock |
| Anaerobes | C. difficile, Bacteroides | Diarrhoea, abdominal pain, recent antibiotics |
| Fungi | Candida, Aspergillus, PJP, Mucor | Prolonged neutropenia > 7d, persistent fever, pulmonary nodules |
| Viruses | HSV, VZV, CMV, respiratory viruses | Vesicular lesions, reactivation in immunosuppressed, coryza |
| Mycobacteria | TB (extrapulmonary in HK) | Prolonged FUO, endemic area, disseminated disease |
| Drug fever | Cytarabine, G-CSF, antibiotics | Temporal correlation, "looks well," eosinophilia |
| Tumour fever | Leukaemia/lymphoma | Positive naproxen test, diagnosis of exclusion |
| Transfusion reaction | FNHTR, ABO incompatibility, bacterial contamination | Temporal relation to blood product administration |
| GVHD | Post-allogeneic HSCT | Rash + diarrhoea + liver dysfunction |
| VTE (DVT/PE) | Cancer hypercoagulability | Leg swelling, pleuritic pain, tachycardia |
| Engraftment syndrome | Neutrophil recovery post-HSCT | Fever + rash + pulmonary oedema at count recovery |
| HLH/MAS | Triggered by EBV, malignancy | Hyperferritinaemia, hypertriglyceridaemia, pancytopenia |
High Yield Summary — Differential Diagnosis of Neutropenic Fever
Primary concern is always INFECTION — treat empirically before the pathogen is identified.
Infectious causes:
- Bacteria are most common; Gram-positive now more frequent (catheter-related), but Gram-negative most dangerous (endotoxic shock)
- Fungi emerge with prolonged neutropenia > 7 days (Aspergillus, Candida)
- Viruses — herpesvirus reactivation (HSV, VZV, CMV) and respiratory viruses
- TB — always consider in HK (endemic); extrapulmonary presentations
Non-infectious causes (consider when fever persists despite adequate antibiotics):
- Drug fever (temporal correlation, "looks well")
- Tumour fever (positive naproxen test)
- Transfusion reaction (exclude ABO incompatibility first)
- GVHD (post-HSCT: rash + diarrhoea + liver dysfunction)
- VTE / PE
- Engraftment syndrome
Clinical approach by site: Examine skin, oral cavity, lungs, abdomen, perianal area, catheter sites, BM biopsy sites, and sinuses — DAILY
Temporal pattern: Day 7–14 = bacteria at nadir; > 7 days neutropenia = fungi; recovery phase = engraftment syndrome / unmasking
Active Recall - Differential Diagnosis of Neutropenic Fever
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 423, Complications of Leukemia — Neutropenic Fever) [2] Senior notes: Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf (p. 11, Haematological Emergencies — Neutropenic fever) [3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 1329–1333, Neutropenic fever) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 572–574, 745, Neutropenic fever) [5] Senior notes: Maksim Medicine Notes.pdf (p. 49, Clinical oncology — Neutropenic fever) [6] Senior notes: Ryan Ho Haemtology.pdf (p. 70, Complications of Leukaemia — Neutropenic Fever) [7] AOS material: AOS - Microbio.pdf (p. 5, Neutropenic fever pathogens) [9] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts.pdf (p. 8, Approach to Mx of neutropenic fever) [10] Senior notes: Ryan Ho Respiratory.pdf (p. 69, Pneumocystis Jirovecii Pneumonia) [11] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf (p. 5, 8, Adverse effects of transfusion)
Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Neutropenic Fever
I. Diagnostic Criteria
Neutropenic fever is a clinical diagnosis — there is no complex scoring system to "confirm" it. The diagnosis is made at the bedside the moment two criteria are met simultaneously.
Neutropenic fever is diagnosed when BOTH of the following are present [1][2][3][4][5][6]:
- Neutropenia: ANC ≤ 0.5 × 10⁹/L (≤ 500/µL), OR ANC ≤ 1.0 × 10⁹/L with a predicted decline to ≤ 0.5 × 10⁹/L within 24–48 hours
- Fever: Single oral temperature ≥ 38.3°C, OR persistent temperature ≥ 38.0°C sustained over ≥ 1 hour
| Term | Definition | Clinical Significance |
|---|---|---|
| Neutropenia | ANC ≤ 1.5 × 10⁹/L | Mild; low infection risk |
| Severe neutropenia | ANC ≤ 0.5 × 10⁹/L | Threshold for neutropenic fever diagnosis; infection risk rises sharply |
| Profound neutropenia | ANC ≤ 0.1 × 10⁹/L | Very high risk; highest mortality; qualifies as high-risk category |
ANC Calculation (from first principles):
Why include bands? Band cells (immature neutrophils with unsegmented nuclei) represent the most mature marrow reserve that has been mobilised. Including them gives a better reflection of the total functional neutrophil pool. In severe neutropenia, even bands will be depleted.
Once the diagnosis of neutropenic fever is made, the next step is risk stratification, which determines the intensity of management:
MASCC (Multinational Association for Supportive Care in Cancer) Risk Index [5]:
| Characteristic | Score |
|---|---|
| Burden of illness: no or mild symptoms | 5 |
| Burden of illness: moderate symptoms | 3 |
| No hypotension (SBP ≥ 90 mmHg) | 5 |
| No COPD | 4 |
| Solid tumour or no previous fungal infection in haematological malignancy | 4 |
| No dehydration requiring IV fluids | 3 |
| Outpatient at onset of fever | 3 |
| Age < 60 years | 2 |
| Maximum | 26 |
MASCC score ≥ 21 → Low risk (PPV ~91%; mortality ~3%) MASCC score < 21 → High risk (mortality ~36%)
High-risk criteria (any one = high risk, requires inpatient IV antibiotics) [5]:
- Anticipated prolonged (≥ 7 days) or profound (ANC < 0.1 × 10⁹/L) neutropenia
- Medical co-morbidities: haemodynamically unstable, deranged LRFT, altered mental state
- MASCC score < 21
Low-risk criteria [5]:
- Expected short duration of neutropenia (≤ 7 days)
- No significant comorbidities
- MASCC score ≥ 21
- In Hong Kong, outpatient management of low-risk patients is seldom practised [5] — most patients are admitted
The algorithm below integrates the GC lecture slide approach [9] and IDSA guidelines. The key principle is: blood cultures first → empirical antibiotics IMMEDIATELY (within 1 hour) → then systematic investigation and risk stratification in parallel.
"Full Hx & P/E (daily): skin, oral, lung, abdomen, perianal, Hickman exit, BM Bx site; over nasal sinus" [9]
GC High Yield — Order of Operations
The approach to management of neutropenic fever [9]:
- Full Hx & P/E (daily)
- Ix: general (CBP, LFT, RFT); blood cultures from central venous catheter through two different ports (peripheral venous puncture if infected catheter suspected)
- Start empirical broad-spectrum antibiotics
- CXR: low risk; CT lung: high risk or symptomatic
- Abdomen CT scan: abdominal pain, tenderness, diarrhea
- Stool × Clostridium difficile cytotoxin & culture: Diarrhea+
- Urine, skin swab, sputum, bronchoalveolar lavage (BAL) for testing (serial serum galactomannan / 1,3 beta-D-glucan): usually done if symptoms or clinical/radiological lesions+ [9]
III. Investigation Modalities
Investigations serve three purposes simultaneously:
- Identify the causative organism (cultures, serology, molecular tests)
- Identify the source/site of infection (imaging, directed cultures)
- Assess severity and organ function (bloods, lactate, ABG)
A. Blood Investigations
| Parameter | Expected Finding | Interpretation / Why |
|---|---|---|
| ANC | ≤ 0.5 × 10⁹/L | Confirms the diagnosis; guides severity grading |
| Haemoglobin | Often ↓ | Marrow suppression → anaemia; concurrent bleeding (thrombocytopaenia) |
| Platelets | Often ↓ | Marrow suppression → thrombocytopaenia → bleeding risk; may need platelet transfusion |
| Peripheral blood smear | May show left shift, blasts, or no abnormal cells | Left shift (band cells, metamyelocytes) suggests severe infection/sepsis [12]; blasts suggest relapsed leukaemia; absence of neutrophils in the context of pancytopaenia |
Why check the differential? Not all neutropaenia is the same. A patient with ANC 0.3 who has some monocytes retained has slightly better innate defence than one with ANC 0.0 and no monocytes at all. The differential also helps detect concurrent lymphopaenia (risk of PJP, viral reactivation) or eosinophilia (drug reaction, parasitic infection).
Ix: general (CBP, LFT, RFT) [9][5]
| Test | Expected Finding | Interpretation |
|---|---|---|
| Creatinine / eGFR | May be ↑ | Sepsis-induced AKI (pre-renal → intrinsic); dehydration; nephrotoxic drugs (aminoglycosides, amphotericin B) |
| Urea | May be disproportionately ↑ compared to Cr | Pre-renal AKI (dehydration, sepsis); also raised in GI bleeding (e.g. from thrombocytopaenic mucosal bleeding) |
| ALT / AST | May be ↑ | "Shock liver" from hypoperfusion; hepatic candidiasis; drug hepatotoxicity |
| ALP / GGT | May be ↑ | Biliary obstruction (cholangitis); hepatic infiltration (hepatosplenic candidiasis) |
| Bilirubin | May be ↑ | Sepsis; hepatic dysfunction; haemolysis (if transfusion reaction) |
| Albumin | Often ↓ | Negative acute-phase reactant; chronic illness; capillary leak in sepsis |
Bloods: CBC d/c, LRFT, CaPO₄ lactate [5]
| Test | Key Findings | Why |
|---|---|---|
| Na⁺ | May be ↓ | SIADH from infection/drugs; or dilutional from IV fluid resuscitation |
| K⁺ | May be ↑ or ↓ | ↑K⁺ in AKI, tumour lysis syndrome (TLS); ↓K⁺ from GI losses (diarrhoea, vomiting) |
| Ca²⁺ / PO₄ | Abnormal in TLS | Look for evidence of tumour lysis syndrome: hyperK, hyperPO₄, hypoCa, ↑uric acid, ↑LDH [4] |
| Lactate | ↑ in sepsis | Lactate > 2 mmol/L indicates tissue hypoperfusion; lactate > 4 mmol/L suggests septic shock and mandates aggressive resuscitation; serial lactate is used to guide response to treatment |
Why is lactate so important? In sepsis, vasodilation + capillary leak → inadequate oxygen delivery to tissues → cells switch to anaerobic glycolysis → pyruvate is converted to lactate. Rising lactate = worsening tissue hypoxia = failing resuscitation. It is the single best prognostic marker in sepsis.
| Marker | Utility | Interpretation |
|---|---|---|
| CRP | ↑ in infection and inflammation | Non-specific; rises within 6–8 hours; useful for trending response to treatment; note that CRP can be elevated by tumour, surgery, and drugs |
| Procalcitonin (PCT) | More specific for bacterial infection | PCT < 0.5 ng/mL makes bacterial infection less likely; PCT > 2 ng/mL strongly suggests bacterial sepsis. Useful for antibiotic stewardship (de-escalation when PCT trending down). PCT is NOT elevated by viral infections or steroids |
| ESR | ↑ in infection and inflammation | Very non-specific; slow to rise and fall; limited utility in acute setting |
| Serum ferritin | Markedly ↑ in HLH/MAS | Ferritin > 10,000 µg/L highly suggestive of HLH (haemophagocytic lymphohistiocytosis) |
| Test | Finding | Significance |
|---|---|---|
| PT / INR, APTT, Fibrinogen | Prolonged PT/APTT, ↓fibrinogen, ↑D-dimer | DIC (disseminated intravascular coagulation) — triggered by Gram-negative sepsis, APML, or severe sepsis of any cause; check clotting to guide blood product support |
| Finding | Interpretation |
|---|---|
| Metabolic acidosis (↓pH, ↓HCO₃⁻, ↑lactate) | Lactic acidosis from septic shock — tissue hypoperfusion |
| Respiratory alkalosis (↓pCO₂) | Early sepsis — tachypnoea driven by cytokines |
| Hypoxia (↓pO₂) | Pneumonia, ARDS, pulmonary oedema from fluid overload |
B. Microbiological Investigations (The Centrepiece)
Blood cultures from central venous catheter through two different ports (peripheral venous puncture if infected catheter suspected) [9]
| Aspect | Detail | Rationale |
|---|---|---|
| Timing | Immediately, before starting antibiotics [5][13] | Once antibiotics are given, cultures may be sterilised and the opportunity to identify the organism is lost |
| Number | At least 2 sets (1 set = 1 aerobic + 1 anaerobic bottle) | Multiple sets increase sensitivity (single set: ~65%; 2 sets: ~80%; 3 sets: ~96%) and help distinguish true bacteraemia from contamination |
| Sites | From CVC through two different lumens/ports + peripheral venous puncture [3][4][9] | Differential time to positivity (DTTP): if CVC culture turns positive ≥ 2 hours before the peripheral culture, it suggests catheter-related bloodstream infection (CRBSI); peripheral site also avoids false positives from catheter biofilm contamination |
| Volume | Adults: 20–30 mL per set (10 mL per bottle) | Volume is the single most important factor for culture yield — underfilling bottles is the most common error |
Differential Time to Positivity (DTTP)
If the blood culture drawn from the CVC becomes positive ≥ 2 hours earlier than the peripheral blood culture drawn simultaneously, this strongly suggests the catheter is the source of infection (CRBSI). This is because the bacterial load is higher at the catheter biofilm, so the culture detects growth sooner. This distinction matters because CRBSI may require catheter removal.
"Urine, Skin swab, sputum, Bronchoalveolar lavage (BAL) for testing... usually done if symptoms or clinical/radiological lesions+" [9]
| Specimen | When to Collect | Key Points |
|---|---|---|
| Urine culture | All patients (routine); especially with urinary symptoms or indwelling catheter | Note: pyuria may be absent in neutropenic patients (no neutrophils to produce WBCs in urine) — a negative dipstick does NOT exclude UTI |
| Sputum culture (including AFB smear) | Productive cough; respiratory symptoms | May be difficult to produce adequate sample in mucositis; if unable, consider induced sputum or BAL |
| Stool | Diarrhoea+ [9] | Stool for C. difficile cytotoxin and culture [9][3][4]; also consider stool culture for other enteric pathogens, ova and parasites |
| Skin / wound swab | Cellulitis, catheter exit site erythema, skin lesions | Culture for bacteria + fungi; consider biopsy for persistent or atypical lesions (e.g. ecthyma gangrenosum) |
| CSF (lumbar puncture) | Meningism, altered consciousness, focal neurology | Only if safe (no raised ICP on CT brain first; platelet count adequate → correct to > 50 × 10⁹/L before LP); send for cell count, protein, glucose, Gram stain, culture, viral PCR, cryptococcal antigen if relevant |
| Bronchoalveolar lavage (BAL) | Persistent pulmonary infiltrates unresponsive to empirical antibiotics; suspicion of PJP, Aspergillus, or atypical pneumonia | Send for bacterial culture, fungal culture, AFB, galactomannan, PJP stain/PCR, viral PCR (respiratory panel); usually done if symptoms or clinical/radiological lesions+ [9] |
| Test | Target Pathogen | Interpretation | When to Order |
|---|---|---|---|
| Serum galactomannan (GM) | Aspergillus | GM is a cell wall component of Aspergillus released during fungal growth; serial monitoring [9]; GM index > 0.5 (single) or > 0.7 (BAL) is positive; Sensitivity ~70%, Specificity ~90% in haem-onc patients | Persistent fever > 4–7 days despite antibiotics; high-risk patients (prolonged neutropenia, HSCT) |
| 1,3 β-D-glucan (BDG) | Pan-fungal (Candida, Aspergillus, PJP — but NOT Mucorales or Cryptococcus) | BDG is a cell wall component of most fungi; > 80 pg/mL is positive; Sensitivity 77%, Specificity 85% | Same as above; complements galactomannan; particularly useful for PJP (Sens ~95%) |
| CMV PCR (viral load) | CMV reactivation | Quantitative PCR; detectable viral load indicates reactivation; rising titres warrant pre-emptive treatment | Post-HSCT, post-organ transplant, prolonged lymphopaenia |
| EBV PCR (viral load) | EBV reactivation / PTLD | Rising EBV viral load suggests risk of post-transplant lymphoproliferative disorder | Post-HSCT, post-organ transplant |
| HSV / VZV PCR | HSV, VZV | PCR of vesicle swab or blood; confirms herpetic infection | Vesicular skin lesions, atypical oral ulcers |
| Respiratory virus multiplex PCR | Influenza, RSV, adenovirus, parainfluenza, SARS-CoV-2 | Nasopharyngeal aspirate (NPA) or swab; rapid results | Upper/lower respiratory symptoms, coryza |
| HIV serology | HIV | Should be checked if not previously done; HIV causes severe immunosuppression and changes the differential (PJP, TB, Cryptococcus, Talaromyces) | New diagnosis of severe infection in young patient; unexplained lymphopaenia |
| Cryptococcal antigen (CrAg) | Cryptococcus neoformans | Serum and/or CSF CrAg; highly sensitive and specific | Suspected meningitis in immunocompromised; headache + fever |
Galactomannan vs β-D-Glucan — Know the Difference
| Galactomannan | 1,3 β-D-Glucan | |
|---|---|---|
| Specificity | Aspergillus-specific | Pan-fungal (most fungi except Mucor and Crypto) |
| Source | Aspergillus cell wall | Cell wall of most fungi |
| False positives | Piperacillin-tazocin (Tazocin), amoxicillin-clavulanate | Haemodialysis membranes, albumin infusions, some antibiotics |
| Role | Serial monitoring for invasive aspergillosis | Screening for any invasive fungal infection |
Exam pearl: Galactomannan can be falsely positive in patients receiving piperacillin-tazocin (Tazocin) — which is the most commonly used first-line empirical antibiotic in neutropenic fever. Be aware of this when interpreting results.
C. Imaging Investigations
CXR: low risk; CT lung: high risk or symptomatic [9]
| Finding | Interpretation | Caveat |
|---|---|---|
| Consolidation / infiltrate | Pneumonia (bacterial, fungal, viral) | Consolidation may be absent due to inability to mount inflammatory response [5] — a normal CXR does NOT rule out pneumonia in a neutropenic patient |
| Bilateral diffuse ground-glass | PJP, viral pneumonia, pulmonary oedema, ARDS | Clinical correlation required |
| Pleural effusion | Parapneumonic effusion, empyema, or non-infectious (malignant) | May warrant diagnostic thoracocentesis |
| Multiple cavitating lesions | Septic emboli (from endocarditis or line sepsis), Aspergillus, Nocardia, TB | Consider echocardiogram to rule out endocarditis |
| Normal CXR | Does NOT exclude pulmonary infection | Low sensitivity in neutropenic patients; proceed to CT if clinical suspicion is high |
CT lung: high risk or symptomatic [9]
| Finding | Pathogen Suggested | Why |
|---|---|---|
| "Halo sign" (ground-glass halo surrounding a nodule) | Invasive pulmonary aspergillosis (IPA) — early sign | The halo represents haemorrhage around the fungal nodule due to angioinvasion by Aspergillus hyphae; best seen early (Day 0–5 of disease) |
| "Air-crescent sign" (crescent of air within a nodule) | IPA — late sign | Occurs as neutrophils recover and necrotic fungal tissue separates from viable lung → cavity forms; typically seen Day 10–20 |
| "Reversed halo sign" (ring of consolidation around central ground-glass) | Mucormycosis, organising pneumonia | Less specific than halo sign |
| Diffuse bilateral ground-glass opacities | PJP, CMV pneumonitis, viral pneumonia | Correlate with β-D-glucan, CMV PCR, respiratory viral panel |
| Tree-in-bud pattern, centrilobular nodules | TB, atypical mycobacteria, viral bronchiolitis | Send sputum for AFB |
| Wedge-shaped peripheral infarcts | Septic emboli (from CRBSI), pulmonary embolism | Consider echocardiogram; CT pulmonary angiography if PE suspected |
Abdomen CT scan: abdominal pain, tenderness, diarrhea [9]
| Finding | Diagnosis | Key Features |
|---|---|---|
| Caecal wall thickening (> 4 mm), pericolonic fat stranding ± pneumatosis | Neutropenic enterocolitis (typhlitis) | Involvement of caecum/ascending colon; may show intramural air (pneumatosis) suggesting necrosis → perforation risk |
| Colonic wall thickening, "accordion sign" | C. difficile colitis | Pancolitis or segmental; "accordion sign" = alternating bands of contrast-enhancing mucosa and low-density oedema |
| Hepatosplenic micro-abscesses ("bull's-eye" lesions) | Hepatosplenic candidiasis (chronic disseminated candidiasis) | Multiple small low-density lesions in liver and spleen; classically becomes visible as neutrophils recover → "unmasking" |
| Peri-appendiceal inflammation | Appendicitis (may lack typical signs in neutropenia) | CT helps differentiate from typhlitis |
| Finding | Diagnosis | Why |
|---|---|---|
| Mucosal thickening, air-fluid levels, bony erosion | Fungal sinusitis (Aspergillus, Mucor) | Prolonged neutropenia + sinus symptoms; bony erosion suggests invasive fungal disease; may require urgent surgical debridement for Mucor |
| Indication | Finding | Interpretation |
|---|---|---|
| Persistent bacteraemia (especially S. aureus > 48 h despite antibiotics); new murmur; embolic phenomena | Vegetation on valve, abscess, new valvular regurgitation | Infective endocarditis — diagnosed by Modified Duke Criteria [14]; TTE as initial screen; TEE if TTE negative but suspicion high |
D. Special Investigations for Specific Scenarios
| Indication | What to Send | Key Findings |
|---|---|---|
| Suspected meningitis/encephalitis (headache, neck stiffness, altered consciousness, focal neurology) | Cell count, protein, glucose, Gram stain, bacterial culture, viral PCR (HSV, VZV, enterovirus), fungal culture, CrAg, AFB | Must do CT brain first if any concern for raised ICP (altered consciousness, focal signs, papilloedema, seizure) [15]; correct platelets to > 50 × 10⁹/L and INR < 1.5 before LP |
| CSF findings in neutropenic patient | May show ↓WCC (neutropenic → fewer cells in CSF) but still have ↑protein and ↓glucose | Paucity of CSF pleocytosis does NOT exclude meningitis — interpret with caution |
| Indication | Purpose |
|---|---|
| If uncertain whether neutropenia is due to chemotherapy vs. disease relapse; prolonged unexplained cytopenias; suspected marrow infiltration (fungal, mycobacterial) | Assess cellularity, residual disease, marrow fibrosis; culture marrow for fungi/AFB; flow cytometry for relapsed leukaemia |
| Indication | Purpose |
|---|---|
| Atypical skin lesions not responding to empirical therapy; pulmonary nodules on CT; hepatosplenic lesions | Histology (fungal hyphae, granulomata for TB); tissue culture; molecular studies (PCR) |
| Category | Investigations | Key Findings |
|---|---|---|
| Bloods — Routine | CBP d/c, LRFT, CaPO₄, lactate [5][9] | ANC for diagnosis; LRFT for organ dysfunction; lactate for sepsis severity; CaPO₄ for TLS |
| Bloods — Inflammatory | CRP, procalcitonin | Trending CRP; PCT for bacterial vs non-bacterial |
| Bloods — Coagulation | PT/INR, APTT, fibrinogen, D-dimer | DIC screen |
| Bloods — ABG | ABG + lactate | Metabolic acidosis, hypoxia, lactate |
| Cultures — Blood | ≥ 2 sets: from CVC (two ports) + peripheral [9] | Organism identification, DTTP for CRBSI |
| Cultures — Directed | Urine, sputum, stool (C. diff), skin swab, CSF, BAL [9] | Site-specific organism identification |
| Fungal markers | Serial serum galactomannan, 1,3 β-D-glucan [9] | Invasive aspergillosis, pan-fungal screening |
| Viral markers | CMV/EBV PCR, respiratory viral panel, HSV/VZV PCR | Viral reactivation, respiratory viruses |
| Imaging — CXR | Low risk patients; first-line [9] | Pneumonia (may be normal despite infection) |
| Imaging — CT thorax | High risk or symptomatic [9] | Halo sign (Aspergillus), GGO (PJP, viral), emboli |
| Imaging — CT abdomen | Abdominal pain, tenderness, diarrhoea [9] | Typhlitis, C. diff colitis, hepatosplenic candidiasis |
| Imaging — CT sinus | Sinus symptoms, prolonged neutropenia | Fungal sinusitis |
| Special | Echocardiography, LP, BM biopsy, tissue biopsy | As clinically indicated |
The following flowchart summarises the complete diagnostic pathway from presentation to organism identification:
GC Exam — Key Investigation Steps
From GC 102 lecture slides [9], the investigation approach can be summarised as:
- General bloods: CBP, LFT, RFT
- Blood cultures from CVC through two different ports; peripheral venous puncture if infected catheter suspected
- CXR: low risk; CT lung: high risk or symptomatic
- CT abdomen: if abdominal pain, tenderness, diarrhea
- Stool × C. difficile cytotoxin & culture: if Diarrhea+
- Urine, Skin swab, sputum, BAL for testing
- Serial serum galactomannan / 1,3 beta-D-glucan: usually done if symptoms or clinical/radiological lesions+
This is the framework to remember for the written paper.
High Yield Summary — Diagnosis and Investigations
Diagnostic Criteria:
- ANC ≤ 0.5 (or ≤ 1.0 with predicted decline to ≤ 0.5 in 48h) + Temp ≥ 38.3°C single or ≥ 38.0°C for ≥ 1h
- Clinical diagnosis — does NOT require positive culture
Risk Stratification:
- MASCC score ≥ 21 = low risk; < 21 = high risk
- High risk if: prolonged neutropenia ≥ 7 days, profound ANC < 0.1, haemodynamic instability, organ dysfunction
Key Investigations:
- Blood cultures FIRST (CVC two ports + peripheral) → then antibiotics within 1 hour
- Baseline: CBP d/c, LRFT, CaPO₄, lactate, coag, ABG
- CXR for all; CT thorax for high risk or symptomatic (look for halo sign)
- CT abdomen for abdominal symptoms (typhlitis, C. diff colitis)
- Stool C. difficile toxin/PCR if diarrhoea
- Serial galactomannan + β-D-glucan if persistent fever > 4–7 days
- Directed cultures: urine, sputum, skin swab, BAL, CSF as clinically indicated
Pitfalls:
- Normal CXR does NOT exclude pneumonia (no neutrophils to form infiltrate)
- Absent pyuria does NOT exclude UTI
- Paucity of CSF pleocytosis does NOT exclude meningitis
- Galactomannan falsely positive with piperacillin-tazocin
Active Recall - Diagnostic Criteria, Algorithm and Investigations for Neutropenic Fever
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 423, Complications of Leukemia — Neutropenic Fever) [2] Senior notes: Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf (p. 11, Haematological Emergencies) [3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 1329–1333, Neutropenic fever) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 572–574, 745, Neutropenic fever) [5] Senior notes: Maksim Medicine Notes.pdf (p. 49, Clinical oncology — Neutropenic fever) [6] Senior notes: Ryan Ho Haemtology.pdf (p. 70, Complications of Leukaemia — Neutropenic Fever) [9] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts.pdf (p. 8, Approach to Mx of neutropenic fever) [12] Senior notes: Ryan Ho Fundamentals.pdf (p. 390–391, Clinical evaluation and Workup) [13] Senior notes: Learning_Points_All_Lectures.txt (Learning Point 3 — febrile neutropenia as medical emergency requiring blood cultures and antibiotics within one hour) [14] Senior notes: Block A - Fever and a murmur_ Valvular heart diseases; Infective endocarditis.pdf (p. 32–33, Modified Duke Criteria) [15] Senior notes: Ryan Ho Neurology.pdf (p. 145, Approach to meningitis investigations)
Management of Neutropenic Fever
Neutropenic fever is a medical emergency because unchecked proliferation of bacteria can lead to rapid progression into septic shock, especially in Gram-negative sepsis [1]. Empirical antibiotics must be started ASAP after immediate septic workup — ideally < 1–2 hours after presentation [1][13].
The management philosophy can be broken down into five pillars:
- Immediate resuscitation and stabilisation
- Empirical antibiotics (the cornerstone — given before culture results)
- Adjustment based on clinical course and culture results (escalation or de-escalation)
- Addition of antifungal agents if fever persists
- Supportive measures (G-CSF, transfusion support, infection prevention)
Before anything else, assess the patient for sepsis and septic shock. This determines the urgency of everything that follows.
| Action | Detail | Rationale |
|---|---|---|
| ABCDE approach | Airway, Breathing, Circulation, Disability, Exposure | Standard emergency assessment; a neutropenic patient in septic shock needs the same resuscitation as any other septic patient |
| IV access | Establish peripheral IV (even if CVC present) | Peripheral access ensures drug delivery if CVC is the source of infection and needs removal |
| Fluid resuscitation | IV crystalloid (0.9% NaCl or Ringer's Lactate) 30 mL/kg bolus over 1–3 hours if haemodynamically unstable | Septic shock causes vasodilation and capillary leak → intravascular volume depletion → organs underperfused; fluids restore circulating volume |
| Vasopressors | Noradrenaline first-line if MAP < 65 mmHg despite adequate fluid resuscitation | Noradrenaline causes vasoconstriction (α₁ agonist) → restores SVR and MAP → maintains organ perfusion |
| Oxygen | Supplemental O₂ to maintain SpO₂ > 94% | Tissue hypoxia worsens lactic acidosis |
| Monitoring | Continuous cardiac monitoring, hourly BP/Pulse/UO, serial lactate | Lactate clearance > 20% in first 6 hours indicates adequate resuscitation |
III. Empirical Antibiotic Therapy — The Cornerstone
The principle of empirical therapy is timely ( < 1–2 hours) administration of broad-spectrum antibiotics that cover most pathogens, especially P. aeruginosa [1]
Why anti-pseudomonal cover is mandatory: Pseudomonas aeruginosa produces endotoxin (LPS) that triggers a fulminant inflammatory cascade → septic shock within hours. Without empirical cover, mortality from Pseudomonas bacteraemia in neutropenic patients exceeds 30–40%. Every hour of delay in appropriate antibiotics increases mortality by approximately 7%.
B. Choice of Empirical Regimen — By Risk Category
Empirical IV broad-spectrum anti-pseudomonal antibiotics for a course of at least 7 days [5]
The standard approach is anti-pseudomonal monotherapy. The following agents are first-line options:
| Drug | Dose | Mechanism | Why This Drug |
|---|---|---|---|
| IV Piperacillin-tazobactam (Tazocin) 4.5g Q6–8h [5][6][3] | 4.5g Q6–8h IVI | Beta-lactam + beta-lactamase inhibitor; inhibits bacterial cell wall synthesis; tazobactam extends spectrum to cover many beta-lactamase producers | Covers Gram-negatives (including Pseudomonas), many Gram-positives, and anaerobes; most commonly used first-line in HK |
| Ceftazidime (Fortum) 1–2g Q8h IV [5][6] | 1–2g Q8h IV | 3rd-generation cephalosporin with excellent anti-pseudomonal activity | Good Gram-negative cover but poor Gram-positive cover; no anaerobic cover |
| Cefepime 2g Q8–12h IV [5][6][3] | 2g Q8–12h IVI | 4th-generation cephalosporin; broader Gram-positive cover than ceftazidime while maintaining anti-pseudomonal activity | Better balance of Gram-positive and Gram-negative cover |
| Meropenem 1g Q8h IVI [5][6][3] | 1g Q8h IVI | Carbapenem; broadest spectrum beta-lactam; inhibits cell wall synthesis; resistant to most beta-lactamases including ESBLs and AmpC | Reserved for patients at high risk of resistant organisms (ESBL producers, prior colonisation); avoid as first-line to prevent carbapenem resistance |
| Imipenem-cilastatin 500mg Q6h IVI [5][6][3] | 500mg Q6h IVI | Carbapenem (same class as meropenem); cilastatin prevents renal metabolism of imipenem | Alternative carbapenem; lowers seizure threshold more than meropenem (avoid in CNS infections or seizure history) |
GC High Yield — First-Line Antibiotic Choice
From GC 102 [9]: The emphasis is on starting empirical broad-spectrum antibiotics after cultures. In Hong Kong practice, Tazocin (piperacillin-tazobactam) is the most commonly used first-line agent. Carbapenems (meropenem) are reserved for patients with risk factors for resistant organisms or documented ESBL-producing infections.
ADD additional antibiotics for selected cases [6][3][4]:
| Indication | Agent to Add | Dose | Rationale |
|---|---|---|---|
| Haemodynamic instability / septic shock | Aminoglycoside: IV Gentamicin or Amikacin [5][6] | Gentamicin 5 mg/kg Q24h or Amikacin 15 mg/kg Q24h | Synergistic bactericidal activity with beta-lactams against Gram-negatives; rapid killing of Pseudomonas; double Gram-negative cover for critically ill patients |
| Suspected MRSA, catheter-related infection, skin/soft tissue infection, pneumonia, or haemodynamic instability | Vancomycin [3][4][6] | 500mg Q6h or 1g Q12h IV (adjust for renal function; target trough 15–20 µg/mL) | Covers MRSA, CoNS (if resistant to beta-lactams), viridans streptococci with reduced penicillin susceptibility |
| Suspected intra-abdominal / perianal infection | Metronidazole | 500mg Q8h IV | Covers anaerobes (Bacteroides, Clostridium spp.) which are not well covered by ceftazidime or cefepime |
| C. difficile colitis | Oral Vancomycin | 125–250mg Q6h PO (NOT IV — oral vancomycin stays in the gut lumen) | IV vancomycin does not reach therapeutic levels in the colonic lumen; oral vancomycin achieves high intraluminal concentrations |
Why not give Vancomycin routinely to everyone? Routine vancomycin adds nephrotoxicity (especially combined with aminoglycosides), promotes VRE (vancomycin-resistant enterococci), and has not been shown to improve outcomes in unselected patients. It should only be added when there is a specific clinical indication [3][4].
Aminoglycoside Safety
Aminoglycosides (gentamicin, amikacin) are nephrotoxic and ototoxic. Monitor renal function and drug levels closely. Extended-interval dosing (once daily) maximises bactericidal activity (concentration-dependent killing) while minimising toxicity. Avoid combining with other nephrotoxins (amphotericin B, vancomycin) when possible — but in life-threatening septic shock, the benefit outweighs the risk.
Low risk (outpatient) — seldom in HK [5]
| Oral Regimen | Dose | Note |
|---|---|---|
| Amoxicillin-clavulanate + Ciprofloxacin [3][4] | Amoxicillin-clavulanate 625mg Q8h PO + Ciprofloxacin 500mg Q12h PO | Only for MASCC ≥ 21, expected neutropenia ≤ 7 days, no comorbidities, reliable patient with caregiver access |
| Levofloxacin monotherapy | 750mg Q24h PO | Alternative if already on fluoroquinolone prophylaxis — NOT appropriate (use IV regimen instead) |
If fluoroquinolone has been used for prophylaxis, use regimen as for high risk [6]. Why? Because the organisms in a patient already on fluoroquinolone prophylaxis have been selected for fluoroquinolone resistance, making oral fluoroquinolone-based therapy unreliable.
Contraindications to outpatient oral therapy:
- MASCC < 21
- Anticipated neutropenia ≥ 7 days or ANC < 0.1
- Haemodynamic instability
- Organ dysfunction (deranged LRFT)
- Altered mental state
- GI symptoms that may impair oral absorption (vomiting, mucositis, diarrhoea)
- Already on fluoroquinolone prophylaxis
- No reliable caregiver or access to emergency care within 1 hour
This is the critical decision point. By 48–72 hours, preliminary culture results may be available and the clinical trajectory becomes clearer.
Key Decisions at 48–72 Hours
| Scenario | Action | Rationale |
|---|---|---|
| Culture positive, susceptible organism | De-escalate to narrowest effective antibiotic | Antibiotic stewardship — reduces side effects, prevents resistance, reduces cost |
| Culture positive, resistant organism | Escalate to appropriate agent (e.g. carbapenem for ESBL-producer; vancomycin for MRSA) | Resistance means the current antibiotic is not killing the organism |
| Culture negative, clinically improving | Continue current regimen; consider de-escalation if afebrile ≥ 48h and ANC recovering | Most neutropenic fever episodes are culture-negative; clinical improvement is the best indicator |
| Culture negative, persistent fever | Repeat cultures; review imaging; check galactomannan/β-D-glucan; consider broadening coverage | Persistent fever suggests inadequate coverage, fungal infection, line sepsis, or non-infectious cause |
| Clinical deterioration | Broaden antibiotics (add aminoglycoside + vancomycin if not already); ICU review; urgent imaging | Impending septic shock; need maximal antimicrobial coverage + haemodynamic support |
V. Antifungal Therapy
Antifungal agents should be initiated for neutropenic fever after 4–7 days (~5 days) of persistent fever despite broad-spectrum antibacterials [3][4][6]
Why 4–7 days? By this point, most bacterial infections should have responded to empirical antibiotics. Persistent fever in the face of adequate antibacterial coverage raises the probability of invasive fungal infection (IFI) — particularly in patients with prolonged neutropenia ( > 7 days) or haematological malignancy.
| Agent | Dose | Spectrum | Advantages | Disadvantages |
|---|---|---|---|---|
| Caspofungin | 70mg IV Day 1, then 50mg Q24h | Candida spp., Aspergillus spp. (fungicidal for Candida, fungistatic for Aspergillus) | Well tolerated; few drug interactions; effective against most Candida including azole-resistant strains | No activity against Mucor, Cryptococcus; only IV formulation |
| Liposomal Amphotericin B (L-AmB) | 3–5 mg/kg/day IV | Broadest spectrum: Candida, Aspergillus, Mucor, Cryptococcus | Covers Mucor (unlike echinocandins and voriconazole); liposomal formulation much less nephrotoxic than conventional amphotericin B | Nephrotoxicity (less than conventional but still significant); infusion-related reactions (fever, rigors); hypokalaemia; expensive |
| Voriconazole | 6 mg/kg Q12h IV Day 1, then 4 mg/kg Q12h IV (or 200mg Q12h PO) | Aspergillus (drug of choice), Candida, Fusarium; NO activity against Mucor | Excellent tissue penetration including CNS; oral formulation available for step-down | Visual disturbances (transient, reversible); hepatotoxicity; photosensitivity; many CYP450 drug interactions; no Mucor cover |
| Posaconazole | 300mg Q12h Day 1, then 300mg Q24h (IV or PO delayed-release tablet) | Aspergillus, Candida, Mucor | Covers Mucor (unlike voriconazole); excellent prophylaxis agent | Needs therapeutic drug monitoring; absorption of oral suspension variable (delayed-release tablet preferred) |
Empirical vs. Pre-emptive vs. Targeted Antifungal Strategy
| Strategy | Trigger | Typical Agents |
|---|---|---|
| Empirical | Persistent fever > 4–7 days despite Abx, no organism identified | Caspofungin, L-AmB |
| Pre-emptive | Positive galactomannan, β-D-glucan, or CT changes (halo sign) but no definitive diagnosis | Voriconazole (for likely Aspergillus), L-AmB |
| Targeted | Confirmed IFI by culture or histology | Agent based on organism identification and susceptibility |
The pre-emptive approach is increasingly favoured in guidelines because it avoids unnecessary antifungal exposure in patients whose persistent fever is due to non-fungal causes, while still treating those with objective evidence of IFI.
| Organism | Drug of Choice | Alternative | Duration |
|---|---|---|---|
| Candida spp. | Echinocandin (caspofungin, micafungin, anidulafungin) for candidaemia | Fluconazole if susceptible (step-down after initial echinocandin) | ≥ 14 days after last positive blood culture + resolution of signs |
| Aspergillus spp. | Voriconazole (primary) | L-AmB, posaconazole, isavuconazole | ≥ 6–12 weeks; guided by clinical and radiological response + immune recovery |
| Mucormycosis | L-AmB (high dose: 5–10 mg/kg/day) + surgical debridement | Posaconazole, isavuconazole (step-down after stabilisation) | Prolonged; surgical debridement is essential; antifungal alone is insufficient |
| PJP (Pneumocystis) | Co-trimoxazole (TMP-SMX) 15–20 mg/kg/day TMP component, divided Q6–8h, for 21 days | Pentamidine IV; clindamycin + primaquine; atovaquone | 21 days; add prednisolone if PaO₂ < 70 mmHg (reduces mortality in moderate-severe PJP) |
MUST check G6PD status before starting co-trimoxazole — sulphamethoxazole (SMX) is a sulphonamide and can cause haemolysis in G6PD-deficient patients. This is particularly important in HK where G6PD deficiency prevalence is approximately 4–5% in males.
The duration depends on whether a source/organism was identified and on neutrophil recovery:
| Scenario | Duration | Rationale |
|---|---|---|
| Known source identified | Complete standard course for that infection (usually 14 days) [3][4] | Treat the infection as you would in any patient, but ensure the full course is completed because the immune system cannot mop up residual organisms |
| Unknown source (FUO), afebrile and ANC recovering | Continue antibiotics until afebrile ≥ 48 hours AND ANC > 0.5 × 10⁹/L [3][4] | The neutrophils are the patient's best defence; once they recover, the risk of relapse drops dramatically |
| Unknown source, afebrile but ANC NOT recovering | Continue antibiotics until Day 14 or until ANC > 0.5, whichever comes first; then reassess | Prolonged antibiotics in persistent neutropenia carry risk of C. difficile, fungal superinfection, and resistance; clinical judgement required |
| Persistent fever, no source identified, ANC recovering | Continue antibiotics for 4–5 days after ANC > 0.5; reassess for non-infectious causes | Neutrophil recovery may unmask previously subclinical infections (e.g. hepatosplenic candidiasis) |
Empirical IV broad-spectrum anti-pseudomonal antibiotics for a course of at least 7 days [5]
VII. Supportive Measures
G-CSF (granulocyte colony-stimulating factor) and GM-CSF (granulocyte-macrophage CSF) are NOT recommended for routine use in patients with neutropenic fever [3][4]
| Aspect | Detail |
|---|---|
| Mechanism | G-CSF (filgrastim, pegfilgrastim) stimulates myeloid progenitor proliferation and differentiation → accelerates neutrophil recovery |
| Indication (therapeutic) | Can be "considered" as adjuvant therapy in high-risk patients [3][4] — specifically: septic shock, fungal infection, or severe pneumonia [1][6] |
| When to stop | Stop G-CSF when neutrophil count returns to 1.0 × 10⁹/L [1][6] |
| Why NOT routine? | G-CSF may increase inflammatory response (theoretically worsening ARDS or capillary leak); no consistent survival benefit in randomised trials; cost; fever from G-CSF itself complicates assessment |
| Contraindication | Do NOT give G-CSF concurrently with chemotherapy (can sensitise rapidly dividing myeloid progenitors to the cytotoxic agent → paradoxically worsen myelosuppression) |
Buffy coat (WBC) transfusion: must be irradiated to prevent lymphocyte proliferation (associated with TA-GVHD) [1][6][16]
| Aspect | Detail |
|---|---|
| Indication | Neutropenic fever (ANC < 0.5) PLUS documented infection not responding to broad-spectrum antibiotics + antifungal for ≥ 48 hours [1][6] |
| Dose | 10 units/day for ≥ 4 days and until fever subsides [1][6] |
| Why irradiate? | Irradiation targets lymphocytes in the blood product → prevents lymphocyte proliferation → prevents transfusion-associated graft-versus-host disease (TA-GVHD) [16]; TA-GVHD is almost universally fatal in immunocompromised patients |
| Storage | Room temperature (20–24°C); shelf life only 8 hours [16] — must be used almost immediately after collection |
| Practical limitation | Rarely requested by physicians other than haematologists [16]; logistically challenging due to extremely short shelf life |
Emergency — No Irradiated Blood Available
If an immunocompromised patient urgently requires blood products and irradiated products are unavailable: Ask the blood bank for the oldest bag of blood — once blood is stored for > 14 days, the lymphocytes should have died, reducing the risk of TA-GVHD [16].
Patients should be placed in reverse-barrier isolation [3][4]
| Measure | Detail | Rationale |
|---|---|---|
| Reverse-barrier isolation | Patient in a single room; healthcare workers gown, glove, mask before entering | Protects the patient FROM the environment (opposite of contact isolation which protects the environment from the patient) |
| Hand hygiene | Alcohol hand rub before and after patient contact | Single most effective infection prevention measure |
| Face mask | Patient wears mask when leaving room; visitors screened for illness | Reduces airborne pathogen exposure |
| HEPA filtration / positive pressure rooms | HSCT recipients should be placed in rooms with positive pressure and high-efficiency particulate air (HEPA) filtration [3][4] | Positive pressure prevents unfiltered corridor air from entering the room; HEPA filters remove Aspergillus spores (3–5 µm) |
| No plants or flowers | Plants and dried or fresh flowers should not be allowed in hospital rooms of neutropenic patients [3][4] | Soil and stagnant water harbour Aspergillus and other moulds |
| Low-bacterial diet | Low-microbial diet consisting of well-cooked food [3][4] | Avoids raw foods that may carry Gram-negative bacteria, Listeria, Salmonella; often instituted but may not reduce occurrence of infection or fever [3][4] |
| Product | Trigger | Target |
|---|---|---|
| Packed RBCs | Hb < 70 g/L (or < 80 g/L if symptomatic / cardiac disease) | Correct anaemia from marrow suppression |
| Platelets | PLT < 10 × 10⁹/L (prophylactic) or < 20 if febrile / bleeding | Prevent/treat haemorrhage |
| FFP / Cryoprecipitate | DIC with active bleeding or PT/APTT > 1.5× normal | Correct coagulopathy |
VIII. Prevention of Neutropenic Fever
Prevention is divided into antimicrobial prophylaxis and growth factor prophylaxis.
| Type | Agent | Indication | Mechanism / Rationale |
|---|---|---|---|
| Antibacterial prophylaxis | Levofloxacin 500mg QD PO [3][4] | High-risk neutropenic patients (expected ANC < 0.5 for > 7 days) | Effectively reduces febrile events and invasive Gram-negative infections [3][4]; fluoroquinolones have excellent bioavailability and broad Gram-negative cover. Disadvantage: selects for fluoroquinolone-resistant organisms and does not cover Gram-positives |
| Antifungal prophylaxis | Posaconazole 300mg QD PO or Fluconazole 200–400mg QD PO | Prolonged and profound neutropenia; HSCT recipients; AML induction chemotherapy [2] | Reduces invasive candidiasis (fluconazole) and both candidiasis + aspergillosis (posaconazole); posaconazole preferred for AML/MDS patients as it also covers Aspergillus |
| Antiviral prophylaxis | Aciclovir 400mg BD PO or Valaciclovir 500mg QD–BD | HSV/VZV seropositive patients undergoing intensive chemotherapy or HSCT | Prevents herpesvirus reactivation (HSV mucositis, VZV shingles) during immunosuppression |
| PJP prophylaxis | Co-trimoxazole (TMP-SMX) 480mg QD or 960mg 3 times/week | Patients on prolonged steroids, purine analogues (fludarabine), alemtuzumab, temozolomide, post-HSCT | Prevents Pneumocystis jirovecii pneumonia; most effective prophylactic agent; check G6PD first |
Azathioprine and Neutropenic Fever — Exam Pearl
Azathioprine can cause neutropenic fever if metabolised excessively to the toxic metabolite 6-TGTP [17]. Before starting azathioprine:
- Check TPMT enzyme activity — low TPMT → excess 6-MP → toxicity
- Check NUDT15 enzyme activity — more common in HK/Asian populations → excess 6-TGTP → severe myelosuppression
- Check if the patient is taking xanthine oxidase inhibitors (allopurinol, febuxostat) — XO is crucial for converting 6-MP to inactive metabolites; inhibition → drug accumulation → bone marrow toxicity
A patient with IBD or autoimmune disease who develops neutropenic fever on azathioprine is a common exam scenario.
Colony stimulating factors [3][4]:
| Agent | Indication for PRIMARY Prophylaxis | Timing |
|---|---|---|
| G-CSF (filgrastim 5 µg/kg/day SC or pegfilgrastim 6mg SC single dose) | Chemotherapy regimen with ≥ 20% risk of febrile neutropenia (e.g. dose-dense regimens, CHOP-14 for lymphoma) | Start 24–72 hours after completion of chemotherapy; continue until ANC recovery > 1.0 |
| Secondary prophylaxis | Patient who experienced neutropenic fever in a prior chemotherapy cycle and dose reduction is not acceptable | Same timing as above |
Why not give G-CSF to everyone? In regimens with < 10% risk of febrile neutropenia, the cost and side effects (bone pain, rarely splenic rupture, leukaemoid reaction) outweigh the benefit. For regimens with 10–20% risk, consider if patient has additional risk factors (age > 65, poor performance status, prior febrile neutropenia).
IX. Special Management Scenarios
| Decision | When | Action |
|---|---|---|
| Catheter salvage (try to keep the line) | CoNS, Enterococcus, Gram-negative (non-complicated); tunnel tract infection absent; patient clinically stable | Antibiotic lock therapy (instilling concentrated antibiotic into the catheter lumen for 8–12 hours) + systemic antibiotics |
| Catheter removal (must remove the line) | S. aureus, Candida spp., Pseudomonas, mycobacteria, tunnel tract infection, persistent bacteraemia > 72h despite appropriate antibiotics, haemodynamic instability, septic emboli | Remove catheter + systemic antibiotics (S. aureus CRBSI → minimum 14 days IV antibiotics after line removal; Candida → 14 days after last positive culture) |
| Aspect | Management |
|---|---|
| Medical | Bowel rest (NBM), IV fluids, broad-spectrum antibiotics with anaerobic cover (Tazocin or carbapenem + metronidazole), G-CSF consideration |
| Surgical | Indicated for: perforation, uncontrolled haemorrhage, clinical deterioration despite maximal medical therapy; surgery carries very high mortality in neutropenic patients — avoid if possible |
| Phase | Agent | Duration |
|---|---|---|
| Primary therapy | Voriconazole (preferred) or isavuconazole | ≥ 6–12 weeks minimum; continue until clinical and radiological resolution + immune recovery |
| Salvage therapy | L-AmB, posaconazole, caspofungin (combination) | For refractory or intolerant patients |
| Surgical | Resection of localised pulmonary lesion if adjacent to great vessels and risk of haemorrhage | Debulk large lesions or prevent fatal haemoptysis |
| Phase | Action | Key Agents |
|---|---|---|
| Immediate (0–1 hour) | Blood cultures → empirical IV broad-spectrum Abx | Tazocin / Cefepime / Meropenem ± Gentamicin ± Vancomycin |
| 48–72 hours | Reassess: culture results, clinical response | Targeted therapy if culture positive; continue empirical if culture negative and improving |
| Day 4–7 | Persistent fever? Add antifungal | Caspofungin / L-AmB / Voriconazole |
| Ongoing | Duration: treat until afebrile ≥ 48h + ANC > 0.5; or complete standard course if source identified | Minimum 7 days; 14 days if source identified |
| Supportive | G-CSF (selected), buffy coat (refractory), reverse isolation, transfusion support | Filgrastim; irradiated WBC transfusion; packed RBCs, platelets |
| Prevention | Prophylaxis for high-risk patients | Levofloxacin (antibacterial), posaconazole/fluconazole (antifungal), aciclovir (antiviral), co-trimoxazole (PJP) |
High Yield Summary — Management of Neutropenic Fever
Immediate:
- Blood cultures (CVC + peripheral) → empirical IV anti-pseudomonal antibiotics WITHIN 1 HOUR
- First-line: IV Tazocin 4.5g Q6–8h (HK practice)
- Add aminoglycoside if haemodynamically unstable; add vancomycin only for specific indications (MRSA, line sepsis, skin infection, pneumonia)
At 48–72 hours:
- Culture positive → targeted therapy
- Culture negative + improving → continue
- Culture negative + persistent fever → reassess; repeat cultures, CT thorax, fungal markers
Day 4–7 persistent fever:
- Add empirical antifungal: caspofungin or L-AmB or voriconazole
Duration:
- Known source: complete standard course (14 days)
- Unknown source: continue until afebrile ≥ 48h AND ANC > 0.5 × 10⁹/L
- Minimum 7 days
Supportive:
- G-CSF: NOT routine; consider in septic shock, fungal infection, severe pneumonia
- Buffy coat: ANC < 0.5 + documented infection not responding to Abx + antifungal for ≥ 48h; must be irradiated
- Reverse isolation, hand hygiene, HEPA filtration for HSCT, no plants/flowers, low-bacterial diet
Prevention:
- Levofloxacin prophylaxis for high-risk patients (reduces Gram-negative infections)
- Posaconazole/fluconazole for antifungal prophylaxis
- Aciclovir for antiviral prophylaxis
- Co-trimoxazole for PJP prophylaxis (check G6PD first)
- G-CSF primary prophylaxis if chemotherapy regimen has ≥ 20% risk of febrile neutropenia
Active Recall - Management of Neutropenic Fever
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 423–424, Complications of Leukemia — Neutropenic Fever) [2] Senior notes: Block A - High white cell count_ acute and chronic leukaemia; bone marrow transplantation; immunogenetics.pdf (p. 9, Supportive treatment of acute leukemia) [3] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p. 1332, Neutropenic fever — Treatment and Prevention) [4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p. 575, Neutropenic fever — Treatment and Prevention) [5] Senior notes: Maksim Medicine Notes.pdf (p. 49, Neutropenic fever — Management) [6] Senior notes: Ryan Ho Haemtology.pdf (p. 71, Neutropenic Fever — Management) [9] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts.pdf (p. 8, Approach to Mx of neutropenic fever) [13] Senior notes: Learning_Points_All_Lectures.txt (Learning Point 3 — febrile neutropenia as medical emergency) [16] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf (p. 5, 8, 22, Leukocytes / Buffy coat, Irradiated blood products) [17] Senior notes: Block A - Chronic diarrhoea_ irritable bowel syndrome and inflammatory bowel disease.pdf (p. 45, Azathioprine — TPMT, NUDT15, XO inhibitors)
Complications of Neutropenic Fever
Complications of neutropenic fever span a wide spectrum — from the immediate life-threatening consequences of uncontrolled infection to the iatrogenic consequences of the treatments themselves, to the paradoxical syndromes that arise when the immune system recovers. Understanding these from first principles helps you anticipate, recognise, and manage them.
I. Complications of the Infection Itself
This is the most feared and most immediately lethal complication.
| Aspect | Detail |
|---|---|
| Pathophysiology | Unchecked proliferation of bacteria can lead to rapid progression into septic shock, especially in Gram-negative sepsis [1]. Gram-negative endotoxin (LPS) activates TLR4 on macrophages → massive release of TNF-α, IL-1β, IL-6 → systemic vasodilation (↓SVR) + capillary leak (fluid shifts from intravascular to interstitial space) + myocardial depression → distributive shock. Without neutrophils to contain the infection at its source, the bacterial load in the blood escalates exponentially. |
| Mortality | ~50% if septic shock develops (compared to ~11% overall for neutropenic fever) [5] |
| Clinical features | Hypotension (SBP < 90 mmHg or MAP < 65 mmHg) refractory to fluid resuscitation, tachycardia, warm peripheries initially (distributive shock) → cold peripheries later (decompensation), oliguria, altered consciousness, rising lactate > 2 mmol/L |
| Why is it worse in neutropenic patients? | In immunocompetent patients, neutrophils localise and contain infection early. In neutropenic patients, there is no containment — bacteria disseminate freely from the primary site (gut, catheter, lung) into the bloodstream. By the time hypotension develops, the bacterial burden is already overwhelming. |
| Management | Sepsis-3 bundle: IV crystalloid 30 mL/kg, vasopressors (noradrenaline) if MAP < 65, empirical broad-spectrum antibiotics within 1 hour, lactate monitoring Q2–4h, source control |
| Aspect | Detail |
|---|---|
| Pathophysiology | Severe sepsis (especially Gram-negative) → massive tissue factor release + endothelial damage → simultaneous activation of coagulation cascade throughout the vasculature → consumption of clotting factors and platelets → microthrombi in small vessels (organ ischaemia) + paradoxical bleeding (consumptive coagulopathy). In acute promyelocytic leukaemia (APML/APL), the granules of malignant promyelocytes themselves contain pro-coagulant and fibrinolytic substances → DIC even before chemotherapy [13]. |
| Clinical features | Bleeding from multiple sites (venepuncture sites, mucosal surfaces, GI tract), petechiae, purpura, acral ischaemia (fingertip gangrene), organ dysfunction |
| Lab findings | ↑PT/INR, ↑APTT, ↓fibrinogen, ↑D-dimer, ↓platelets, fragmented RBCs (schistocytes) on peripheral blood smear |
| Management | Treat the underlying cause (infection/leukaemia); supportive: platelet transfusion (target > 50 if bleeding), cryoprecipitate (target fibrinogen > 1.0 g/L), FFP (if PT/APTT > 1.5× normal with bleeding) |
| Organ | Mechanism in Sepsis | Clinical Manifestation |
|---|---|---|
| Kidneys | Hypoperfusion + direct endotoxin injury → acute tubular necrosis (ATN) | Oliguria, rising creatinine, metabolic acidosis; may require renal replacement therapy |
| Lungs | Capillary leak + neutrophil-mediated (paradoxically, even in neutropenic patients, small numbers of remaining immune cells + complement activation can cause endothelial damage) → ARDS | Bilateral infiltrates on CXR, refractory hypoxaemia (PaO₂/FiO₂ < 300), need for mechanical ventilation |
| Liver | "Shock liver" — hepatocyte ischaemia from hypoperfusion | Massively elevated ALT/AST (often > 1000 U/L), rising bilirubin, coagulopathy |
| CNS | Septic encephalopathy — microabscesses, cerebral oedema, metabolic derangement | Confusion, agitation, obtundation, coma |
| Heart | Septic cardiomyopathy — direct myocardial depression by TNF-α and IL-1β | ↓EF on echocardiography, elevated troponin, haemodynamic deterioration |
Why does organ failure beget more organ failure? Each failing organ compounds the insult to others. For example, AKI → fluid overload and metabolic acidosis → worsens cardiac function → worsens renal perfusion. This vicious cycle is why septic shock with MODS carries such high mortality.
When bacteraemia is not contained, organisms can seed distant sites:
| Complication | Organism | Pathophysiology | Clinical Clue |
|---|---|---|---|
| Infective endocarditis | S. aureus, viridans streptococci, enterococci | Bacterial seeding of cardiac valves (especially if pre-existing valvular abnormality or prosthetic valve) → vegetation formation | Persistent bacteraemia (S. aureus > 48–72h despite antibiotics), new murmur, embolic phenomena (splinter haemorrhages, Janeway lesions) |
| Cerebral abscess / meningitis | Gram-negatives, fungi (Aspergillus, Cryptococcus), Toxoplasma | Haematogenous spread to CNS; or direct extension from sinusitis (Aspergillus, Mucor) | Headache, altered consciousness, focal neurology, seizures; CT showing ring-enhancing lesion or meningeal enhancement |
| Hepatosplenic candidiasis | Candida spp. | Disseminated candidiasis seeds liver and spleen → microabscesses; classically becomes symptomatic as neutrophils recover ("unmasking") | Persistent fever during neutrophil recovery, ↑ALP, "bull's-eye" lesions on CT/MRI liver and spleen |
| Osteomyelitis / septic arthritis | S. aureus, Gram-negatives | Haematogenous seeding of bone/joints | Bone pain, joint swelling; MRI is best diagnostic modality |
| Mycotic aneurysm | S. aureus, Salmonella | Bacterial infection of arterial wall → weakening → aneurysm formation → rupture | Pulsatile mass, sudden haemodynamic collapse |
II. Site-Specific Infectious Complications
| Aspect | Detail |
|---|---|
| Definition | Necrotising inflammation of the caecum (and sometimes other bowel segments) in a neutropenic patient |
| Pathophysiology | Chemotherapy damages caecal mucosa → mucosal breakdown → bacterial invasion of the bowel wall → transmural inflammation ± necrosis. The caecum is most vulnerable because it has the thinnest wall and poorest blood supply in the large bowel. |
| Clinical features | RIF pain, diarrhoea (± bloody), abdominal distension, fever; signs may be subtle due to neutropenia |
| Diagnosis | CT abdomen: caecal wall thickening ( > 4mm), pericolonic fat stranding, ± intramural gas (pneumatosis intestinalis) |
| Complications | Perforation → faecal peritonitis → septic shock; haemorrhage; stricture (late) |
| Management | Medical: bowel rest (NBM), IV fluids, broad-spectrum antibiotics with anaerobic cover, G-CSF consideration. Surgical: only for perforation, uncontrolled haemorrhage, or clinical deterioration despite maximal medical therapy — surgery carries extremely high mortality in neutropenic patients |
| Aspect | Detail |
|---|---|
| When | Prolonged neutropenia ( > 7 days); haematological malignancy; post-HSCT [1][7] |
| Pathophysiology | Aspergillus spores (ubiquitous in the environment) are inhaled → normally cleared by alveolar macrophages and neutrophils. In neutropenia, spores germinate into hyphae → angioinvasion (Aspergillus hyphae have a tropism for blood vessels) → thrombosis → tissue infarction and necrosis → haemorrhagic infarct |
| Clinical features | Persistent fever despite broad-spectrum antibiotics, pleuritic chest pain, haemoptysis |
| Imaging | CT thorax: halo sign (early — ground-glass halo around nodule representing haemorrhage) → air-crescent sign (late — crescent of air as necrotic tissue separates at neutrophil recovery) |
| Complications | Fatal haemoptysis (if fungal nodule erodes into a major pulmonary artery), dissemination to brain (cerebral aspergillosis — brain abscess), skin, other organs |
| Mortality | 30–60% even with treatment; higher in disseminated disease |
| Aspect | Detail |
|---|---|
| Pathophysiology | Fungal spores colonise the sinuses → invade through sinus mucosa and bone → extension to orbits and brain (rhinocerebral mucormycosis) |
| Clinical clue | Facial pain, nasal discharge (often bloody), necrotic black eschar on palate or nasal turbinates (pathognomonic), proptosis, cranial nerve palsies |
| Urgency | Surgical emergency — requires urgent surgical debridement of necrotic tissue + high-dose L-AmB. Delay is fatal. |
| Aspect | Detail |
|---|---|
| Why in neutropenic fever? | Broad-spectrum antibiotics (especially the first-line agents used empirically) disrupt normal colonic flora → C. difficile overgrowth → toxin production (toxins A and B) → mucosal inflammation and necrosis |
| Clinical features | Watery diarrhoea (may be bloody), abdominal pain, fever; may be masked by neutropenia |
| Diagnosis | Stool for C. difficile cytotoxin and culture [9] or stool PCR for toxin genes |
| Complications | Toxic megacolon (colonic dilation > 6 cm with systemic toxicity), perforation, peritonitis |
| Treatment | Oral vancomycin 125mg Q6h PO (first-line) or fidaxomicin 200mg BD PO; severe/fulminant: add IV metronidazole 500mg Q8h; colectomy for toxic megacolon with perforation |
III. Complications of Treatment (Iatrogenic)
| Complication | Causative Agent | Mechanism | Clinical Features |
|---|---|---|---|
| Nephrotoxicity | Aminoglycosides (gentamicin, amikacin), amphotericin B (conventional > liposomal), vancomycin | Aminoglycosides accumulate in proximal tubular cells → direct tubular injury; amphotericin B causes renal vasoconstriction + direct tubular toxicity; vancomycin at high troughs damages tubules | Rising creatinine, oliguria, electrolyte wasting (Mg²⁺, K⁺ with amphotericin B); monitor drug levels and renal function |
| Ototoxicity | Aminoglycosides | Accumulate in cochlear and vestibular hair cells → irreversible damage | Hearing loss (high-frequency first), tinnitus, vertigo; often irreversible |
| C. difficile colitis | Any broad-spectrum antibiotic (especially fluoroquinolones, clindamycin, cephalosporins) | Disruption of colonic microbiome → C. difficile overgrowth | Diarrhoea, fever, abdominal pain (see above) |
| Drug fever | Beta-lactams, vancomycin, amphotericin B | Hypersensitivity or direct pyrogenicity | Persistent fever that resolves on drug cessation; may be accompanied by eosinophilia or rash |
| Hepatotoxicity | Voriconazole, isoniazid (if TB treatment), co-trimoxazole | Drug-induced liver injury (DILI) | Elevated ALT/AST, jaundice; requires LFT monitoring |
| Visual disturbances | Voriconazole | Transient inhibition of retinal function (mechanism not fully elucidated; related to drug binding to visual pigments) | Photopsia (flashes of light), altered colour perception, blurred vision; reversible; occurs in ~30% of patients |
| Photosensitivity | Voriconazole (long-term) | UVA-induced phototoxicity → risk of skin malignancy (squamous cell carcinoma) with prolonged use | Exaggerated sunburn, erythema; counsel on sun avoidance and photoprotection |
| Bone marrow suppression | Co-trimoxazole, ganciclovir (for CMV), linezolid | Folate antagonism (co-trimoxazole), direct myelotoxicity (ganciclovir, linezolid) | Worsened cytopaenia — the very problem you are trying to manage |
| QT prolongation | Fluoroquinolones, azole antifungals (voriconazole, fluconazole), macrolides | Block cardiac hERG potassium channels → delayed ventricular repolarisation | Risk of torsades de pointes; perform baseline ECG; avoid combining QT-prolonging agents |
Azathioprine-Induced Neutropenic Fever
A patient with atopic dermatitis died of neutropenic fever after being on azathioprine [17]. This is a cautionary tale from HK clinical practice. Azathioprine-induced myelosuppression is predictable and preventable — always check TPMT and NUDT15 enzyme activity before prescribing, and check for concomitant xanthine oxidase inhibitors (allopurinol, febuxostat) [17].
Given that neutropenic patients require frequent transfusions (packed RBCs for anaemia, platelets for thrombocytopaenia, buffy coat for refractory infections), transfusion-related complications are common:
| Complication | Mechanism | Clinical Features | Prevention |
|---|---|---|---|
| Febrile non-haemolytic transfusion reaction (FNHTR) | Cytokines from residual leucocytes in blood products; most common transfusion reaction [16] | Fever, chills during or after transfusion; patient otherwise well | Use leucodepleted products; pre-medication with paracetamol |
| Transfusion-associated graft-versus-host disease (TA-GVHD) | Donor lymphocytes in non-irradiated blood products attack recipient tissues; almost universally fatal in immunocompromised patients [16] | Fever, maculopapular rash, diarrhoea, liver dysfunction, pancytopaenia; onset 1–6 weeks post-transfusion | Blood products must be irradiated for immunocompromised patients [16] to eliminate donor lymphocytes |
| Transfusion-related acute lung injury (TRALI) | Anti-HLA or anti-neutrophil antibodies in donor plasma activate recipient neutrophils in the pulmonary vasculature → capillary leak → non-cardiogenic pulmonary oedema | Acute respiratory distress within 6 hours of transfusion; bilateral infiltrates on CXR; hypoxia | Use male-only plasma donors (reduces anti-HLA antibodies from multiparous female donors) |
| Iron overload (haemosiderosis) | Chronic transfusions → each unit of packed RBCs contains ~250 mg iron; body has no active excretion mechanism for iron | Organ damage: cardiomyopathy, liver cirrhosis, endocrine dysfunction (DM, hypogonadism) | Iron chelation therapy (deferasirox, deferoxamine) if ferritin > 1000 or > 20 units transfused |
| Bacterial contamination of blood products | Bacteria (especially in platelet concentrates stored at room temperature) | High fever, rigors, hypotension shortly after starting transfusion | Bacterial screening of platelet products; pathogen reduction technology |
Emergency — No Irradiated Blood Available
If irradiated products are unavailable in an emergency: ask the blood bank for the oldest bag of blood — after > 14 days of storage, donor lymphocytes should have died, reducing TA-GVHD risk [16].
Indwelling central venous catheters (Hickman, PICC, port) are essential for chemotherapy delivery but are a double-edged sword:
| Complication | Mechanism | Management |
|---|---|---|
| Catheter-related bloodstream infection (CRBSI) | Biofilm formation on catheter surface by skin commensals (CoNS, S. aureus) or gut-translocated organisms; bacteria seed into bloodstream | Antibiotic lock therapy ± systemic antibiotics; catheter removal for S. aureus, Candida, Pseudomonas, tunnel infection, or persistent bacteraemia > 72h |
| Catheter-related thrombosis | Foreign body in vein → endothelial damage + stasis → Virchow's triad → DVT of subclavian/internal jugular vein | Anticoagulation (LMWH → warfarin or DOAC); catheter removal if extensive thrombus or no longer needed |
| Mechanical complications | Pneumothorax (at insertion), catheter fracture, air embolism, catheter tip malposition | Procedural precautions; CXR post-insertion |
IV. Immune Reconstitution Syndromes
These are paradoxical complications that occur when the immune system recovers, not when it is suppressed. They are increasingly recognised and can be confusing to the uninitiated.
Paradoxical deterioration with fever and a new inflammatory focus or progression of a preexisting inflammatory focus can happen in temporal relationship to the recovery of the immune defect [18]
| Aspect | Detail |
|---|---|
| Examples of immune recovery triggers | Recovery of CD4 lymphocyte count after antiretroviral treatment (HIV-related IRIS); recovery of ANC after chemotherapy (Myeloid Reconstitution Syndrome) [18] |
| Pathophysiology | During profound immunosuppression, subclinical infections exist but cannot mount an inflammatory response (hence "occult" — no symptoms, no imaging findings). When the immune system recovers (ANC rises, CD4 count rises), it suddenly "sees" these pathogens and mounts a vigorous inflammatory response → paradoxical clinical worsening despite the infection itself not spreading |
| Clinical features | New fever during neutrophil recovery, new or worsening pulmonary infiltrates, new lymphadenopathy, worsening of skin lesions, worsening of hepatosplenic candidiasis (previously occult microabscesses now become visible on imaging as neutrophils infiltrate them) |
| Classic examples | Hepatosplenic candidiasis unmasked at neutrophil recovery; mycobacterial IRIS (paradoxical TB worsening); Aspergillus IRIS (enlarging pulmonary nodules despite adequate antifungal therapy and rising ANC) |
| Management | Distinguish from true treatment failure — the key clue is that IRIS occurs at the time of immune recovery, not at nadir. Continue antimicrobials; consider short-course corticosteroids if inflammatory response is life-threatening (e.g. worsening respiratory failure); do NOT escalate antifungals/antibiotics unnecessarily |
IRIS vs Treatment Failure — How to Tell the Difference
| Feature | IRIS | Treatment Failure |
|---|---|---|
| Timing | At immune recovery (rising ANC or CD4) | At nadir or during persistent immunosuppression |
| Cultures | Usually negative (pathogen being cleared) | May be positive (pathogen persisting or new pathogen) |
| Response to escalating antimicrobials | No improvement (it's inflammation, not infection) | Improvement with broader coverage |
| Response to corticosteroids | Improvement | Worsening (immunosuppression potentiates infection) |
| Aspect | Detail |
|---|---|
| Context | Post-HSCT, specifically around the time of neutrophil engraftment (ANC > 0.5 for 3 consecutive days, typically Day 10–14 post-autologous HSCT, Day 14–21 post-allogeneic HSCT) |
| Pathophysiology | Newly produced neutrophils and monocytes release cytokines (IL-1, IL-6, TNF-α, GM-CSF) in an exuberant, dysregulated manner → capillary leak, tissue inflammation |
| Clinical features | Non-infectious fever, skin rash (erythematous, maculopapular), non-cardiogenic pulmonary oedema (capillary leak → bilateral infiltrates), diarrhoea, weight gain (fluid retention); can mimic acute GVHD |
| Distinction from acute GVHD | Engraftment syndrome occurs earlier (at engraftment), responds to corticosteroids, and is self-limiting. GVHD occurs later and involves specific target organs (skin, liver, gut) with histological confirmation. |
| Management | Corticosteroids (methylprednisolone 1–2 mg/kg/day); supportive care; resolves within days |
V. Complications of Prolonged Neutropenia
| Aspect | Detail |
|---|---|
| Why it occurs | Prolonged empirical broad-spectrum antibiotics exert selective pressure → resistant organisms survive and proliferate. Key resistant phenotypes in HK: ESBL-producing Enterobacterales, carbapenem-resistant organisms (CRO), MRSA, VRE, multi-drug resistant Pseudomonas |
| Clinical consequence | Subsequent episodes of neutropenic fever may be caused by organisms resistant to the standard empirical regimen → higher mortality, need for "last-resort" agents (colistin, tigecycline) |
| Prevention | Antibiotic stewardship: de-escalate when possible, narrow spectrum when culture results available, avoid unnecessarily prolonged courses |
| Aspect | Detail |
|---|---|
| Risk | Each chemotherapy cycle carries risk of neutropenic fever; patients receiving multiple cycles may have recurrent episodes, each potentially caused by different (and increasingly resistant) organisms |
| Impact | Cumulative organ toxicity from repeated antibiotic courses (nephrotoxicity, C. difficile), psychological burden, chemotherapy delays (dose reductions or cycle postponement to allow marrow recovery) |
| Prevention | G-CSF prophylaxis for regimens with ≥ 20% risk; consider dose reduction or alternative regimen if recurrent life-threatening episodes |
| Aspect | Detail |
|---|---|
| Why it matters | Neutropenic fever may necessitate postponement of the next chemotherapy cycle until the patient recovers → delays in treatment → potentially compromised oncological outcomes (reduced cure rates, higher relapse rates) |
| Balance | The oncologist must weigh the risk of treatment delay against the risk of another episode; G-CSF secondary prophylaxis or dose reduction may be employed to maintain treatment intensity |
| Category | Specific Complications | Key Mechanism | Mortality / Severity |
|---|---|---|---|
| Sepsis / Shock | Septic shock, DIC, MODS | Endotoxin → cytokine storm → vasodilation, capillary leak, organ damage | ~50% mortality in septic shock [5] |
| Metastatic infection | Endocarditis, brain abscess, hepatosplenic candidiasis, osteomyelitis | Haematogenous seeding from primary bacteraemia / fungaemia | Variable; endocarditis and brain abscess carry high mortality |
| Site-specific | Typhlitis, IPA, fungal sinusitis, C. difficile colitis | Mucosal damage + neutropenia → local invasion; antibiotic-induced dysbiosis | Typhlitis: perforation → high mortality; IPA: 30–60% mortality |
| Drug-related | Nephrotoxicity, ototoxicity, hepatotoxicity, C. difficile, drug fever, bone marrow suppression, QT prolongation | Direct organ toxicity or hypersensitivity | Usually manageable if recognised early |
| Transfusion-related | FNHTR, TA-GVHD, TRALI, iron overload, bacterial contamination | Immune-mediated or infectious | TA-GVHD: almost universally fatal |
| Vascular access | CRBSI, catheter thrombosis | Biofilm, endothelial injury | CRBSI: significant morbidity; thrombosis: PE risk |
| Immune reconstitution | IRIS / Myeloid Reconstitution Syndrome, engraftment syndrome | Paradoxical inflammatory response at immune recovery | Variable; can be fatal if misdiagnosed as treatment failure |
| Antimicrobial resistance | MDR organisms | Selective pressure from prolonged antibiotics | Higher mortality in subsequent infections |
| Oncological | Delayed chemotherapy, dose reduction | Neutropenic fever necessitates treatment postponement | Potentially compromised cure rates |
High Yield Summary — Complications of Neutropenic Fever
Infection-related:
- Septic shock (mortality ~50%) — especially Gram-negative endotoxic shock
- DIC — consumptive coagulopathy; bleeding + thrombosis simultaneously
- MODS — kidneys, lungs, liver, CNS, heart
- Metastatic infection — endocarditis, brain abscess, hepatosplenic candidiasis
Site-specific:
- Neutropenic enterocolitis (typhlitis) — RIF pain, caecal wall thickening, risk of perforation
- Invasive pulmonary aspergillosis — halo sign, angioinvasion, haemoptysis, high mortality
- C. difficile colitis — antibiotic-induced; risk of toxic megacolon
- Invasive fungal sinusitis — surgical emergency
Treatment-related:
- Nephrotoxicity (aminoglycosides, amphotericin B, vancomycin)
- TA-GVHD from non-irradiated blood products — almost universally fatal; irradiate all products for immunocompromised patients
- C. difficile from broad-spectrum antibiotics
Immune reconstitution:
- IRIS / Myeloid Reconstitution Syndrome — paradoxical worsening at ANC recovery; distinguish from treatment failure
- Engraftment syndrome — non-infectious fever + rash + pulmonary oedema at HSCT engraftment; responds to steroids
Systemic:
- Antimicrobial resistance from prolonged empirical antibiotics
- Delayed chemotherapy → potentially compromised oncological outcomes
Active Recall - Complications of Neutropenic Fever
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 423, Complications of Leukemia — Neutropenic Fever) [5] Senior notes: Maksim Medicine Notes.pdf (p. 49, Clinical oncology — Neutropenic fever) [7] AOS material: AOS - Microbio.pdf (p. 5, Neutropenic fever pathogens) [9] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts.pdf (p. 8, Approach to Mx) [13] Senior notes: Learning_Points_All_Lectures.txt (Learning Point 2 — APML and DIC; Learning Point 3 — febrile neutropenia as medical emergency) [16] Senior notes: Block A - Fever after a blood transfusion_ transfusion and related problems.pdf (p. 5, 8, 22, Leukocytes / Buffy coat, TA-GVHD, Irradiated products) [17] Senior notes: Block A - Treatments for skin diseases (eczema, psoriasis and urticaria).pdf (p. 23, Azathioprine and neutropenic fever) [18] Lecture slides: GC 102. Fever after chemotherapy infections in immunocompromised hosts [Handout].pdf (p. 6, IRIS / Myeloid Reconstitution Syndrome, Prevention of infections)
High Yield Summary
Definition:
- Neutropenic fever = ANC ≤ 0.5 × 10⁹/L (or ≤ 1.0 with predicted decline to ≤ 0.5 in 48h) + single oral temp ≥ 38.3°C or sustained ≥ 38.0°C for ≥ 1 hour
Key Numbers:
- Occurs in 10–50% of solid tumours; higher in haematological malignancies
- Only 20–30% are culture-positive
- Mortality ~11% overall, ~50% with septic shock
- Nadir: Day 7–10 (Taxanes D4–5; post-HSCT D21)
- Neutrophil lifespan: ~2–3 days
Risk Factors: Duration and depth of neutropenia are most important; prolonged ( ≥ 7 days) and profound ( < 0.1) = highest risk
Pathogens:
- Gram-positive now most common (CoNS, S. aureus, viridans strep) — due to catheters
- Gram-negative most dangerous (Pseudomonas, E. coli) — endotoxin → septic shock
- Fungal (Candida, Aspergillus) — with prolonged neutropenia > 7 days
- Viral reactivation (HSV, VZV, CMV)
Clinical Features:
- Fever is often the ONLY sign
- Pus is NOT formed (no neutrophils)
- CXR may be normal despite pneumonia
- Examine: skin, oral cavity, lungs, abdomen, perianal area, catheter sites, BM biopsy sites, sinuses — DAILY
- Avoid DRE
Principle: Medical emergency — start empirical broad-spectrum anti-pseudomonal antibiotics within 1 hour of presentation
High Yield Summary — Differential Diagnosis of Neutropenic Fever
Primary concern is always INFECTION — treat empirically before the pathogen is identified.
Infectious causes:
- Bacteria are most common; Gram-positive now more frequent (catheter-related), but Gram-negative most dangerous (endotoxic shock)
- Fungi emerge with prolonged neutropenia > 7 days (Aspergillus, Candida)
- Viruses — herpesvirus reactivation (HSV, VZV, CMV) and respiratory viruses
- TB — always consider in HK (endemic); extrapulmonary presentations
Non-infectious causes (consider when fever persists despite adequate antibiotics):
- Drug fever (temporal correlation, "looks well")
- Tumour fever (positive naproxen test)
- Transfusion reaction (exclude ABO incompatibility first)
- GVHD (post-HSCT: rash + diarrhoea + liver dysfunction)
- VTE / PE
- Engraftment syndrome
Clinical approach by site: Examine skin, oral cavity, lungs, abdomen, perianal area, catheter sites, BM biopsy sites, and sinuses — DAILY
Temporal pattern: Day 7–14 = bacteria at nadir; > 7 days neutropenia = fungi; recovery phase = engraftment syndrome / unmasking
High Yield Summary — Diagnosis and Investigations
Diagnostic Criteria:
- ANC ≤ 0.5 (or ≤ 1.0 with predicted decline to ≤ 0.5 in 48h) + Temp ≥ 38.3°C single or ≥ 38.0°C for ≥ 1h
- Clinical diagnosis — does NOT require positive culture
Risk Stratification:
- MASCC score ≥ 21 = low risk; < 21 = high risk
- High risk if: prolonged neutropenia ≥ 7 days, profound ANC < 0.1, haemodynamic instability, organ dysfunction
Key Investigations:
- Blood cultures FIRST (CVC two ports + peripheral) → then antibiotics within 1 hour
- Baseline: CBP d/c, LRFT, CaPO₄, lactate, coag, ABG
- CXR for all; CT thorax for high risk or symptomatic (look for halo sign)
- CT abdomen for abdominal symptoms (typhlitis, C. diff colitis)
- Stool C. difficile toxin/PCR if diarrhoea
- Serial galactomannan + β-D-glucan if persistent fever > 4–7 days
- Directed cultures: urine, sputum, skin swab, BAL, CSF as clinically indicated
Pitfalls:
- Normal CXR does NOT exclude pneumonia (no neutrophils to form infiltrate)
- Absent pyuria does NOT exclude UTI
- Paucity of CSF pleocytosis does NOT exclude meningitis
- Galactomannan falsely positive with piperacillin-tazocin
High Yield Summary — Management of Neutropenic Fever
Immediate:
- Blood cultures (CVC + peripheral) → empirical IV anti-pseudomonal antibiotics WITHIN 1 HOUR
- First-line: IV Tazocin 4.5g Q6–8h (HK practice)
- Add aminoglycoside if haemodynamically unstable; add vancomycin only for specific indications (MRSA, line sepsis, skin infection, pneumonia)
At 48–72 hours:
- Culture positive → targeted therapy
- Culture negative + improving → continue
- Culture negative + persistent fever → reassess; repeat cultures, CT thorax, fungal markers
Day 4–7 persistent fever:
- Add empirical antifungal: caspofungin or L-AmB or voriconazole
Duration:
- Known source: complete standard course (14 days)
- Unknown source: continue until afebrile ≥ 48h AND ANC > 0.5 × 10⁹/L
- Minimum 7 days
Supportive:
- G-CSF: NOT routine; consider in septic shock, fungal infection, severe pneumonia
- Buffy coat: ANC < 0.5 + documented infection not responding to Abx + antifungal for ≥ 48h; must be irradiated
- Reverse isolation, hand hygiene, HEPA filtration for HSCT, no plants/flowers, low-bacterial diet
Prevention:
- Levofloxacin prophylaxis for high-risk patients (reduces Gram-negative infections)
- Posaconazole/fluconazole for antifungal prophylaxis
- Aciclovir for antiviral prophylaxis
- Co-trimoxazole for PJP prophylaxis (check G6PD first)
- G-CSF primary prophylaxis if chemotherapy regimen has ≥ 20% risk of febrile neutropenia
High Yield Summary — Complications of Neutropenic Fever
Infection-related:
- Septic shock (mortality ~50%) — especially Gram-negative endotoxic shock
- DIC — consumptive coagulopathy; bleeding + thrombosis simultaneously
- MODS — kidneys, lungs, liver, CNS, heart
- Metastatic infection — endocarditis, brain abscess, hepatosplenic candidiasis
Site-specific:
- Neutropenic enterocolitis (typhlitis) — RIF pain, caecal wall thickening, risk of perforation
- Invasive pulmonary aspergillosis — halo sign, angioinvasion, haemoptysis, high mortality
- C. difficile colitis — antibiotic-induced; risk of toxic megacolon
- Invasive fungal sinusitis — surgical emergency
Treatment-related:
- Nephrotoxicity (aminoglycosides, amphotericin B, vancomycin)
- TA-GVHD from non-irradiated blood products — almost universally fatal; irradiate all products for immunocompromised patients
- C. difficile from broad-spectrum antibiotics
Immune reconstitution:
- IRIS / Myeloid Reconstitution Syndrome — paradoxical worsening at ANC recovery; distinguish from treatment failure
- Engraftment syndrome — non-infectious fever + rash + pulmonary oedema at HSCT engraftment; responds to steroids
Systemic:
- Antimicrobial resistance from prolonged empirical antibiotics
- Delayed chemotherapy → potentially compromised oncological outcomes
Chronic Lymphocytic Leukaemia
Chronic lymphocytic leukaemia is a low-grade B-cell lymphoproliferative disorder characterized by the progressive accumulation of mature but functionally incompetent lymphocytes in the blood, bone marrow, and lymphoid tissues.
Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myeloproliferative neoplasm characterized by the uncontrolled proliferation of mature and maturing granulocytes, driven by the BCR-ABL1 fusion gene resulting from the Philadelphia chromosome translocation t(9;22).